1
|
Prétet JL, Dalstein V, Touzé A, Beby-Defaux A, Soussan P, Jacquin É, Birembaut P, Clavel C, Mougin C, Rousseau A, Lacau Saint Guily J. High levels of HPV16-L1 antibody but not HPV16 DNA load or integration predict oropharyngeal patient outcome: The Papillophar study. Clin Exp Med 2023; 23:87-96. [PMID: 35199231 DOI: 10.1007/s10238-022-00796-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Accepted: 01/18/2022] [Indexed: 11/30/2022]
Abstract
The incidence of oropharyngeal cancers (OPC) is increasing in the world. Among OPC, those induced by human papillomaviruses have a better prognosis than non-HPV-associated OPC. The objective of this study was to highlight the relevance of HPV16 load, HPV16 DNA integration and HPV16-L1 serology on progression-free survival and overall survival of OPC patients. The PAPILLOPHAR cohort consists of 362 patients with oropharyngeal squamous cell carcinomas prospectively followed up for 5 years after treatment. Tumor biopsies and sera were collected at inclusion to investigate tumor HPV DNA/RNA characteristics and HPV16 L1 serology, respectively. Twenty-seven percent of tumor biopsies were HPV DNA- and RNA-positive and HPV16 represented 93% of HPV-positive cases. Among them, neither HPV16 viral load nor HPV16 DNA integration was associated with overall survival (OS) or progression-free survival (PFS). In contrast, high anti-HPV16 L1 antibody titers were significantly associated with a better OS and PFS. This study reveals that HPV16 load and integration are not relevant prognosis biomarkers in OPC patients.Clinical Relevance: High levels of HPV16 L1 antibodies may be useful to predict OPC patient outcome following treatment.ClinicalTrials.gov Identifier: NCT00918710, May 2017.
Collapse
Affiliation(s)
- Jean-Luc Prétet
- Laboratoire de Biologie Cellulaire Et Moléculaire, PC-Bio, EA3181, UBFC, Université de Franche-Comté, CNR Papillomavirus, Centre Hospitalier Régional Universitaire, CHRU Besancon, Boulevard A Fleming, 25030, Besançon Cedex, France.
| | - Véronique Dalstein
- Inserm UMR-S 1250 P3Cell, Université de Reims Champagne-Ardenne, SFR CAP-Santé, 51092, Reims, France.,Laboratoire de Biopathologie, CHU Maison Blanche, Reims, France
| | - Antoine Touzé
- UMR INRAE ISP Équipe Biologie Des Infections À Polyomavirus, Faculté Des Sciences, Pharmaceutiques 31 avenue Monge, 37200, Tours, France
| | - Agnès Beby-Defaux
- Service de Virologie, CHU de Poitiers, Faculté de Médecine Et de Pharmacie de Poitiers, EA 4331 LITEC, Université de Poitiers, Poitiers, France
| | - Patrick Soussan
- Laboratoire de Virologie, Hôpital Tenon, CRSA Inserm U 938 Sorbonne University, Paris, France
| | - Élise Jacquin
- Laboratoire de Biologie Cellulaire Et Moléculaire, PC-Bio, EA3181, UBFC, Université de Franche-Comté, CNR Papillomavirus, Centre Hospitalier Régional Universitaire, CHRU Besancon, Boulevard A Fleming, 25030, Besançon Cedex, France.,INSERM UMR-S 1193, Faculté de Pharmacie, Châtenay-Malabry, France
| | - Philippe Birembaut
- Inserm UMR-S 1250 P3Cell, Université de Reims Champagne-Ardenne, SFR CAP-Santé, 51092, Reims, France.,Laboratoire de Biopathologie, CHU Maison Blanche, Reims, France
| | - Christine Clavel
- Inserm UMR-S 1250 P3Cell, Université de Reims Champagne-Ardenne, SFR CAP-Santé, 51092, Reims, France.,Laboratoire de Biopathologie, CHU Maison Blanche, Reims, France
| | - Christiane Mougin
- Laboratoire de Biologie Cellulaire Et Moléculaire, PC-Bio, EA3181, UBFC, Université de Franche-Comté, CNR Papillomavirus, Centre Hospitalier Régional Universitaire, CHRU Besancon, Boulevard A Fleming, 25030, Besançon Cedex, France.,INSERM UMR1098, Univ. Bourgogne Franche-Comté, 25000, Besançon Cedex, France
| | - Alexandra Rousseau
- Research Platform Paris-East (URCEST-CRC-CRB), Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, France
| | - Jean Lacau Saint Guily
- Department of Otolaryngology, HNS, Tenon Hospital, APHP and Sorbonne University, Paris, France.,Department of OL-HNS, Rothschild Foundation Hospital and Sorbonne University, Paris, France
| | | |
Collapse
|
2
|
Guisier F, Deslee G, Birembaut P, Escarguel B, Chapel F, Bota S, Métayer J, Lachkar S, Capron F, Homasson JP, Taulelle M, Quintana M, Raspaud C, Messelet D, Benzaquen J, Hofman P, Baddredine J, Paris C, Cales V, Laurent P, Vignaud JM, Ménard O, Copin MC, Ramon P, Bouchindhomme B, Tavernier JY, Quintin I, Quiot JJ, Galateau-Sallé F, Zalcman G, Piton N, Thiberville L. Endoscopic follow-up of low-grade precancerous bronchial lesions in high-risk patients: long-term results of the SELEPREBB randomised multicentre trial. Eur Respir J 2022; 60:13993003.01946-2021. [PMID: 35236723 DOI: 10.1183/13993003.01946-2021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2021] [Accepted: 01/15/2022] [Indexed: 01/29/2023]
Abstract
BACKGROUND 3-9% of low-grade preinvasive bronchial lesions progress to cancer. This study assessed the usefulness of an intensive bronchoscopy surveillance strategy in patients with bronchial lesions up to moderate squamous dysplasia. METHODS SELEPREBB (ClinicalTrials.gov NCT00213603) was a randomised study conducted in 17 French centres. After baseline lung computed tomography (CT) and autofluorescence bronchoscopy (AFB) to exclude lung cancer and bronchial severe squamous dysplasia or carcinoma in situ (CIS), patients were assigned to standard surveillance (arm A) with CT and AFB at 36 months or to intensive surveillance (arm B) with AFB every 6 months. Further long-term data were obtained with a median follow-up of 4.7 years. RESULTS 364 patients were randomised (A: 180, B: 184). 27 patients developed invasive lung cancer and two developed persistent CIS during the study, with no difference between arms (OR 0.63, 95% CI 0.20-1.96, p=0.42). Mild or moderate dysplasia at baseline bronchoscopy was a significant lung cancer risk factor both at 3 years (8 of 74 patients, OR 6.9, 95% CI 2.5-18.9, p<0.001) and at maximum follow-up (16 of 74 patients, OR 5.9, 95% CI 2.9-12.0, p<0.001). Smoking cessation was significantly associated with clearance of bronchial dysplasia on follow-up (OR 0.12, 95% CI 0.01-0.66, p=0.005) and with a reduced risk of lung cancer at 5 years (OR 0.15, 95% CI 0.003-0.99, p=0.04). CONCLUSION Patients with mild or moderate dysplasia are at very high risk for lung cancer at 5 years, with smoking cessation significantly reducing the risk. Whereas intensive bronchoscopy surveillance does not improve patient outcomes, the identification of bronchial dysplasia using initial bronchoscopy maybe useful for risk stratification strategies in lung cancer screening programmes.
Collapse
Affiliation(s)
- Florian Guisier
- Dept of Pneumology, Normandie Univ, UNIROUEN, LITIS Lab QuantIF team EA4108, CHU Rouen and Inserm CIC-CRB 1404, Rouen, France
| | - Gaëtan Deslee
- Dept of Pneumology, CHU de Reims, Inserm UMR 1250, Université de Reims-Champagne Ardenne, Reims, France
| | | | | | - Françoise Chapel
- Laboratoire d'Anatomie Pathologique, CHI Toulon La Seyne sur Mer, Toulon, France
| | | | | | | | | | | | | | | | | | - Daniel Messelet
- Laboratoire d'Anatomie et Cytologie Pathologiques, Toulouse, France
| | - Jonathan Benzaquen
- Dept of Pulmonary Medicine and Oncology, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Nice, France.,Institute of Research on Cancer and Aging (IRCAN), Université Côte d'Azur, FHU OncoAge, CNRS UMR7284, INSERM U1081, Nice, France
| | - Paul Hofman
- Institute of Research on Cancer and Aging (IRCAN), Université Côte d'Azur, CNRS, INSERM, Nice, France.,Laboratory of Clinical and Experimental Pathology, Université Côte d'Azur, FHU OncoAge, BB-0033-00025, Centre Hospitalier Universitaire de Nice, Nice, France
| | | | - Christophe Paris
- INSERM U1085 IRSET and Service de Santé au Travail et de Pathologie Professionnelle et Environnementale, CHRU Pontchaillou, Rennes, France
| | - Valérie Cales
- Laboratoire d'Anatomie Pathologique, CH de Pau, Pau, France
| | | | | | - Olivier Ménard
- Service de Pneumologie, CHU Nancy, Hôpital Brabois, Vandoeuvre les Nancy, France
| | | | - Philippe Ramon
- Clinique des Maladies Respiratoires, CHRU Lille, Hôpital Calmette, Lille, France
| | | | | | - Isabelle Quintin
- Service d'Anatomie Pathologique, CHU Brest, Hôpital Morvan, Brest, France
| | | | - Françoise Galateau-Sallé
- Laboratoire d'Anatomie Pathologique, CHU de Caen, Caen, France.,Dept of BioPathology Centre Leon Berard, Lyon, France
| | - Gérard Zalcman
- Service de Pneumologie, CHU de Caen, Caen, France.,Thoracic Oncology Dept, Université de Paris, Hôpital Bichat Claude Bernard, Paris, France
| | - Nicolas Piton
- Service de Pathologie, Normandie Université, UNIROUEN, Inserm U1245, CHU Rouen, Rouen, France
| | - Luc Thiberville
- Dept of Pneumology, Normandie Univ, UNIROUEN, LITIS Lab QuantIF team EA4108, CHU Rouen and Inserm CIC-CRB 1404, Rouen, France
| |
Collapse
|
3
|
Mazza C, Gaydou V, Eymard JC, Birembaut P, Untereiner V, Côté JF, Brocheriou I, Coeffic D, Villena P, Larré S, Vuiblet V, Piot O. Identification of Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer by Fourier-Transform Infrared Micro-Imaging. Cancers (Basel) 2021; 14:cancers14010021. [PMID: 35008184 PMCID: PMC8750189 DOI: 10.3390/cancers14010021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Revised: 12/09/2021] [Accepted: 12/17/2021] [Indexed: 11/24/2022] Open
Abstract
Simple Summary Assessing the tumor response to chemotherapy is a paramount predictive step to improve patient care. Infrared spectroscopy probes the chemical composition of samples, and in combination with statistical multivariate processing, presents the capacity to highlight subtle molecular alterations associated with malignancy characteristics. Microscopic infrared imaging of tissue samples reveals spectral heterogeneity within histological structures, providing a new approach to characterize tumoral heterogeneity. We have taken advantage of the analytical capabilities of mid-infrared spectral imaging to implement a classification model to predict the response of a tumor to chemotherapy. Our development was demonstrated in muscle-invasive bladder cancer (MIBC) by comparing samples from responders and non-responders to neoadjuvant chemotherapy. Abstract Background: Neoadjuvant chemotherapy (NAC) improves survival in responder patients. However, for non-responders, the treatment represents an ineffective exposure to chemotherapy and its potential adverse events. Predicting the response to treatment is a major issue in the therapeutic management of patients, particularly for patients with muscle-invasive bladder cancer. Methods: Tissue samples of trans-urethral resection of bladder tumor collected at the diagnosis time, were analyzed by mid-infrared imaging. A sequence of spectral data processing was implemented for automatic recognition of informative pixels and scoring each pixel according to a continuous scale (from 0 to 10) associated with the response to NAC. The ground truth status of the responder or non-responder was based on histopathological examination of the samples. Results: Although the TMA spots of tumors appeared histologically homogeneous, the infrared approach highlighted spectral heterogeneity. Both the quantification of this heterogeneity and the scoring of the NAC response at the pixel level were used to construct sensitivity and specificity maps from which decision criteria can be extracted to classify cancerous samples. Conclusions: This proof-of-concept appears as the first to evaluate the potential of the mid-infrared approach for the prediction of response to neoadjuvant chemotherapy in MIBC tissues.
Collapse
Affiliation(s)
- Camille Mazza
- Jean Godinot Institute, 51100 Reims, France; (C.M.); (J.-C.E.)
| | - Vincent Gaydou
- BioSpecT (Translational BioSpectroscopy) EA 7506, SFR Santé, Université de Reims Champagne-Ardenne, 51100 Reims, France; (V.G.); (S.L.)
| | | | - Philippe Birembaut
- Department of Biopathology, University Hospital of Reims, 51100 Reims, France;
| | - Valérie Untereiner
- Cellular and Tissular Imaging Platform (PICT), Université de Reims Champagne-Ardenne, 51100 Reims, France;
| | - Jean-François Côté
- Department of Biopathology, Hôpital de la Pitié-Salpêtrière, APHP, 51100 Paris, France; (J.-F.C.); (I.B.)
| | - Isabelle Brocheriou
- Department of Biopathology, Hôpital de la Pitié-Salpêtrière, APHP, 51100 Paris, France; (J.-F.C.); (I.B.)
| | - David Coeffic
- Polyclinique Courlancy, 51100 Reims, France; (D.C.); (P.V.)
| | | | - Stéphane Larré
- BioSpecT (Translational BioSpectroscopy) EA 7506, SFR Santé, Université de Reims Champagne-Ardenne, 51100 Reims, France; (V.G.); (S.L.)
- Department of Urology, University Hospital of Reims, 51100 Reims, France
| | - Vincent Vuiblet
- BioSpecT (Translational BioSpectroscopy) EA 7506, SFR Santé, Université de Reims Champagne-Ardenne, 51100 Reims, France; (V.G.); (S.L.)
- Department of Biopathology, University Hospital of Reims, 51100 Reims, France;
- Correspondence: (V.V.); (O.P.)
| | - Olivier Piot
- BioSpecT (Translational BioSpectroscopy) EA 7506, SFR Santé, Université de Reims Champagne-Ardenne, 51100 Reims, France; (V.G.); (S.L.)
- Cellular and Tissular Imaging Platform (PICT), Université de Reims Champagne-Ardenne, 51100 Reims, France;
- Correspondence: (V.V.); (O.P.)
| |
Collapse
|
4
|
Routhier J, Pons S, Freidja ML, Dalstein V, Cutrona J, Jonquet A, Lalun N, Mérol JC, Lathrop M, Stitzel JA, Kervoaze G, Pichavant M, Gosset P, Tournier JM, Birembaut P, Dormoy V, Maskos U. An innate contribution of human nicotinic receptor polymorphisms to COPD-like lesions. Nat Commun 2021; 12:6384. [PMID: 34737286 PMCID: PMC8568944 DOI: 10.1038/s41467-021-26637-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2020] [Accepted: 10/14/2021] [Indexed: 02/07/2023] Open
Abstract
Chronic Obstructive Pulmonary Disease is a generally smoking-linked major cause of morbidity and mortality. Genome-wide Association Studies identified a locus including a non-synonymous single nucleotide polymorphism in CHRNA5, rs16969968, encoding the nicotinic acetylcholine receptor α5 subunit, predisposing to both smoking and Chronic Obstructive Pulmonary Disease. Here we report that nasal polyps from rs16969968 non-smoking carriers exhibit airway epithelium remodeling and inflammation. These hallmarks of Chronic Obstructive Pulmonary Disease occur spontaneously in mice expressing human rs16969968. They are significantly amplified after exposure to porcine pancreatic elastase, an emphysema model, and to oxidative stress with a polymorphism-dependent alteration of lung function. Targeted rs16969968 expression in epithelial cells leads to airway remodeling in vivo, increased proliferation and production of pro-inflammatory cytokines through decreased calcium entry and increased adenylyl-cyclase activity. We show that rs16969968 directly contributes to Chronic Obstructive Pulmonary Disease-like lesions, sensitizing the lung to the action of oxidative stress and injury, and represents a therapeutic target. Human polymorphisms in nicotinic acetylcholine receptor genes have been linked to both smoking and lung diseases like Chronic Obstructive Pulmonary Disease (COPD) or lung cancer. Here the authors identify a direct role for a human coding polymorphism in COPD-like lesions independent of smoke or nicotine exposure.
Collapse
Affiliation(s)
- Julie Routhier
- Université de Reims Champagne-Ardenne, Inserm, P3Cell UMR-S1250, Reims, France
| | - Stéphanie Pons
- Institut Pasteur, Université de Paris, Integrative Neurobiology of Cholinergic Systems, CNRS UMR 3571, Paris, France
| | - Mohamed Lamine Freidja
- Université de Reims Champagne-Ardenne, Inserm, P3Cell UMR-S1250, Reims, France.,Department of Biochemistry and Microbiology, Faculty of Sciences, University of M'sila, M'sila, Algeria
| | - Véronique Dalstein
- Université de Reims Champagne-Ardenne, Inserm, P3Cell UMR-S1250, Reims, France.,Department of Biopathology, CHU of Reims, Reims, France
| | - Jérôme Cutrona
- Université de Reims Champagne-Ardenne, Inserm, P3Cell UMR-S1250, Reims, France
| | - Antoine Jonquet
- Université de Reims Champagne-Ardenne, Inserm, P3Cell UMR-S1250, Reims, France
| | - Nathalie Lalun
- Université de Reims Champagne-Ardenne, Inserm, P3Cell UMR-S1250, Reims, France
| | - Jean-Claude Mérol
- Université de Reims Champagne-Ardenne, Inserm, P3Cell UMR-S1250, Reims, France.,Department of Otorhinolaryngology, CHU of Reims, Reims, France
| | - Mark Lathrop
- McGill University Genome Center, Montréal, QC, Canada
| | - Jerry A Stitzel
- Institute for Behavioral Genetics, University of Colorado, Boulder, CO, USA
| | - Gwenola Kervoaze
- University of Lille, CNRS UMR9017, Inserm U1019, CHU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, Lille, France
| | - Muriel Pichavant
- University of Lille, CNRS UMR9017, Inserm U1019, CHU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, Lille, France
| | - Philippe Gosset
- University of Lille, CNRS UMR9017, Inserm U1019, CHU Lille, Institut Pasteur de Lille, CIIL - Center for Infection and Immunity of Lille, Lille, France
| | - Jean-Marie Tournier
- Université de Reims Champagne-Ardenne, Inserm, P3Cell UMR-S1250, Reims, France
| | - Philippe Birembaut
- Université de Reims Champagne-Ardenne, Inserm, P3Cell UMR-S1250, Reims, France.,Department of Biopathology, CHU of Reims, Reims, France
| | - Valérian Dormoy
- Université de Reims Champagne-Ardenne, Inserm, P3Cell UMR-S1250, Reims, France.
| | - Uwe Maskos
- Institut Pasteur, Université de Paris, Integrative Neurobiology of Cholinergic Systems, CNRS UMR 3571, Paris, France.
| |
Collapse
|
5
|
Diabasana Z, Belgacemi R, Ancel J, Routhier J, Birembaut P, Maskos U, Polette M, Deslée G, Dormoy V. Implication du SNPα5 dans la bronchopneumopathie chronique obstructive. Rev Mal Respir 2021. [DOI: 10.1016/j.rmr.2021.02.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
6
|
Ancel J, Belgacemi R, Perotin JM, Diabasana Z, Dury S, Dewolf M, Bonnomet A, Lalun N, Birembaut P, Polette M, Deslée G, Dormoy V. Sonic hedgehog signalling as a potential endobronchial biomarker in COPD. Respir Res 2020; 21:207. [PMID: 32767976 PMCID: PMC7412648 DOI: 10.1186/s12931-020-01478-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2020] [Accepted: 08/02/2020] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND The hedgehog (HH) pathway has been associated with chronic obstructive pulmonary disease (COPD) in genome-wide association studies and recent studies suggest that HH signalling could be altered in COPD. We therefore used minimally invasive endobronchial procedures to assess activation of the HH pathway including the main transcription factor, Gli2, and the ligand, Sonic HH (Shh). METHODS Thirty non-COPD patients and 28 COPD patients were included. Bronchial brushings, bronchoalveolar lavage fluid (BALF) and bronchial biopsies were obtained from fiberoptic bronchoscopy. Characterization of cell populations and subcellular localization were evaluated by immunostaining. ELISA and RNAseq analysis were performed to identify Shh proteins in BAL and transcripts on lung tissues from non-COPD and COPD patients with validation in an external and independent cohort. RESULTS Compared to non-COPD patients, COPD patients exhibited a larger proportion of basal cells in bronchial brushings (26 ± 11% vs 13 ± 6%; p < 0.0001). Airway basal cells of COPD subjects presented less intense nuclear staining for Gli2 in bronchial brushings and biopsies (p < 0.05). Bronchial BALF from COPD patients contained lower Shh concentrations than non-COPD BALF (12.5 vs 40.9 pg/mL; p = 0.002); SHH transcripts were also reduced in COPD lungs in the validation cohort (p = 0.0001). CONCLUSION This study demonstrates the feasibility of assessing HH pathway activation in respiratory samples collected by bronchoscopy and identifies impaired bronchial epithelial HH signalling in COPD.
Collapse
Affiliation(s)
- Julien Ancel
- University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France.,Department of Pulmonary Medicine, University Hospital of Reims, Hôpital Maison Blanche, 51092, Reims, France
| | - Randa Belgacemi
- University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France
| | - Jeanne-Marie Perotin
- University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France.,Department of Pulmonary Medicine, University Hospital of Reims, Hôpital Maison Blanche, 51092, Reims, France
| | - Zania Diabasana
- University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France
| | - Sandra Dury
- Department of Pulmonary Medicine, University Hospital of Reims, Hôpital Maison Blanche, 51092, Reims, France
| | - Maxime Dewolf
- Department of Pulmonary Medicine, University Hospital of Reims, Hôpital Maison Blanche, 51092, Reims, France
| | - Arnaud Bonnomet
- University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France.,Platform of Cellular and Tissular Imaging (PICT), 51097, Reims, France
| | - Nathalie Lalun
- University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France
| | - Philippe Birembaut
- University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France.,University Hospital of Reims, Hôpital Maison Blanche, Laboratoire de Biopathologie, 51092, Reims, France
| | - Myriam Polette
- University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France.,University Hospital of Reims, Hôpital Maison Blanche, Laboratoire de Biopathologie, 51092, Reims, France
| | - Gaëtan Deslée
- University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France.,Department of Pulmonary Medicine, University Hospital of Reims, Hôpital Maison Blanche, 51092, Reims, France
| | - Valérian Dormoy
- University of Reims Champagne-Ardenne, Inserm, P3Cell UMR-S 1250, SFR CAP-SANTE, 45 rue Cognacq-Jay, 51092, Reims, France.
| |
Collapse
|
7
|
Da Silva J, Jouida A, Ancel J, Dalstein V, Routhier J, Delepine G, Cutrona J, Jonquet A, Dewolf M, Birembaut P, Deslée G, Polette M, Nawrocki-Raby B. FHIT low /pHER2 high signature in non-small cell lung cancer is predictive of anti-HER2 molecule efficacy. J Pathol 2020; 251:187-199. [PMID: 32237123 DOI: 10.1002/path.5439] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Revised: 01/31/2020] [Accepted: 03/24/2020] [Indexed: 01/24/2023]
Abstract
Despite its efficacy in solid tumours, in particular HER2+ breast cancer, HER2-targeted therapy has given rise to disappointing results in non-small cell lung cancer (NSCLC). With the aim of refining the target population for anti-HER2 therapies in NSCLC, we investigated the relationships between HER2 and the tumour suppressor fragile histidine triad (FHIT) in lung tumour cells. First, we observed a negative correlation between FHIT expression and the activated form of HER2 (pHER2) in NSCLC samples and in lung tumour cell lines. Moreover, the silencing or overexpression of FHIT in lung cell lines led to an increase or decrease of HER2 activity, respectively. We also demonstrated that two anti-HER2 drugs, irbinitinib and trastuzumab, restore a more epithelial phenotype and counteract cell invasiveness and growth of FHIT-silenced tumour cell lines. Finally, we showed that the FHITlow /pHER2high phenotype predicts sensitivity to an anti-HER2 therapy in primary tumour cells from NSCLC patients. Our results show that FHIT regulates the activity of HER2 in lung tumour cells and that FHIT-inactivated tumour cells are sensitive to HER2 inhibitors. A new subclass of patients with NSCLC may be eligible for an anti-HER2 therapy. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Jordan Da Silva
- INSERM, Université de Reims Champagne Ardenne, P3Cell UMR-S 1250, SFR CAP SANTE, Reims, France
| | - Amina Jouida
- INSERM, Université de Reims Champagne Ardenne, P3Cell UMR-S 1250, SFR CAP SANTE, Reims, France
| | - Julien Ancel
- INSERM, Université de Reims Champagne Ardenne, P3Cell UMR-S 1250, SFR CAP SANTE, Reims, France.,CHU de Reims, Hôpital Maison Blanche, Service de Pneumologie, Reims, France
| | - Véronique Dalstein
- INSERM, Université de Reims Champagne Ardenne, P3Cell UMR-S 1250, SFR CAP SANTE, Reims, France.,CHU de Reims, Hôpital Maison Blanche, Laboratoire de Pathologie, Reims, France
| | - Julie Routhier
- INSERM, Université de Reims Champagne Ardenne, P3Cell UMR-S 1250, SFR CAP SANTE, Reims, France
| | - Gonzague Delepine
- INSERM, Université de Reims Champagne Ardenne, P3Cell UMR-S 1250, SFR CAP SANTE, Reims, France.,CHU de Reims, Hôpital Robert Debré, Service de Chirurgie Cardio-Vasculaire et Thoracique, Reims, France
| | - Jérôme Cutrona
- INSERM, Université de Reims Champagne Ardenne, P3Cell UMR-S 1250, SFR CAP SANTE, Reims, France
| | - Antoine Jonquet
- INSERM, Université de Reims Champagne Ardenne, P3Cell UMR-S 1250, SFR CAP SANTE, Reims, France
| | - Maxime Dewolf
- CHU de Reims, Hôpital Maison Blanche, Service de Pneumologie, Reims, France
| | - Philippe Birembaut
- INSERM, Université de Reims Champagne Ardenne, P3Cell UMR-S 1250, SFR CAP SANTE, Reims, France.,CHU de Reims, Hôpital Maison Blanche, Laboratoire de Pathologie, Reims, France
| | - Gaëtan Deslée
- INSERM, Université de Reims Champagne Ardenne, P3Cell UMR-S 1250, SFR CAP SANTE, Reims, France.,CHU de Reims, Hôpital Maison Blanche, Service de Pneumologie, Reims, France
| | - Myriam Polette
- INSERM, Université de Reims Champagne Ardenne, P3Cell UMR-S 1250, SFR CAP SANTE, Reims, France.,CHU de Reims, Hôpital Maison Blanche, Laboratoire de Pathologie, Reims, France
| | - Béatrice Nawrocki-Raby
- INSERM, Université de Reims Champagne Ardenne, P3Cell UMR-S 1250, SFR CAP SANTE, Reims, France
| |
Collapse
|
8
|
Belgacemi R, Luczka E, Ancel J, Diabasana Z, Perotin JM, Germain A, Lalun N, Birembaut P, Dubernard X, Mérol JC, Delepine G, Polette M, Deslée G, Dormoy V. Airway epithelial cell differentiation relies on deficient Hedgehog signalling in COPD. EBioMedicine 2020; 51:102572. [PMID: 31877414 PMCID: PMC6931110 DOI: 10.1016/j.ebiom.2019.11.033] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2019] [Revised: 10/11/2019] [Accepted: 11/20/2019] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Hedgehog (HH) pathway is constantly under scrutiny in the context of organ development. Lung morphogenesis requires HH signalling which participates thereafter to the pulmonary homeostasis by regulating epithelial cell quiescence and repair. Since epithelial remodelling is a hallmark of Chronic Obstructive Pulmonary Disease (COPD), we investigated whether the main molecular actors of HH pathway participate to airway epithelial cell differentiation and we analysed their alterations in COPD patients. METHODS Sonic HH (Shh) secretion was assessed by ELISA in airway epithelial cell (AEC) air-liquid interface culture supernatants. HH pathway activation was evaluated by RT-qPCR, western blot and immunostaining. Inhibition of HH signalling was achieved upon Shh chelation during epithelial cell differentiation. HH pathway core components localization was investigated in lung tissues from non-COPD and COPD patients. FINDINGS We demonstrate that progenitors of AEC produced Shh responsible for the activation of HH signalling during the process of differentiation. Preventing the ligand-induced HH activation led to the establishment of a remodelled epithelium with increased number of basal cells and reduced ciliogenesis. Gli2 activating transcription factor was demonstrated as a key-element in the regulation of AEC differentiation. More importantly, Gli2 and Smo were lost in AEC from COPD patients. INTERPRETATION Our data suggest that HH pathway is crucial for airway epithelial cell differentiation and highlight its role in COPD-associated epithelial remodelling.
Collapse
Affiliation(s)
- Randa Belgacemi
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France
| | - Emilie Luczka
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France
| | - Julien Ancel
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France; CHU Reims, Hôpital Maison Blanche, Service de pneumologie, Reims 51092, France
| | - Zania Diabasana
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France
| | - Jeanne-Marie Perotin
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France; CHU Reims, Hôpital Maison Blanche, Service de pneumologie, Reims 51092, France
| | - Adeline Germain
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France
| | - Nathalie Lalun
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France
| | - Philippe Birembaut
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France; CHU Reims, Hôpital Maison Blanche, Laboratoire de biopathologie, Reims 51092, France
| | - Xavier Dubernard
- CHU Reims, Hôpital Robert Debré, Service d'oto-rhino-laryngologie, Reims 51092, France
| | - Jean-Claude Mérol
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France; CHU Reims, Hôpital Robert Debré, Service d'oto-rhino-laryngologie, Reims 51092, France
| | - Gonzague Delepine
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France; CHU Reims, Hôpital Robert Debré, Service de chirurgie cardio-vasculaire et thoracique, Reims 51092, France
| | - Myriam Polette
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France; CHU Reims, Hôpital Maison Blanche, Laboratoire de biopathologie, Reims 51092, France
| | - Gaëtan Deslée
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France; CHU Reims, Hôpital Maison Blanche, Service de pneumologie, Reims 51092, France
| | - Valérian Dormoy
- Université de Reims Champagne-Ardenne, INSERM, P3Cell UMR-S1250, SFR CAP-SANTE, Reims 51097, France.
| |
Collapse
|
9
|
Branchu B, Léon P, Jeglinschi SC, Durlach A, Trigui S, Birembaut P, Larré S. [Interest of reTURB for pTa high grade bladder urothelial carcinoma]. Prog Urol 2019; 30:19-25. [PMID: 31866142 DOI: 10.1016/j.purol.2019.11.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2019] [Revised: 11/01/2019] [Accepted: 11/28/2019] [Indexed: 11/18/2022]
Abstract
INTRODUCTION Second look TURB (Transurethral Resection of Bladder Tumor) is recommended for high-risk pT1 tumors. It is well acquired for tumors classified pT1 high grade but its interest is still discussed for high-grade pTa tumors in the absence of high level of evidence. We evaluated the impact of second-look resection for the high-grade pTa bladder tumor. METHODS We performed a retrospective study in 2 centers from 2007 to 2016. We included all urothelial tumors classified pTa high grade. We studied the anatomopathological findings of reTURB and its consequences on survival without recurrence and progression. RESULTS Eighty-four patients were included. Thirty-five patients (41.7%) had reTURB and residual tumor was found in 42.9% of cases. The anatomopathology of reTURB was in 20% of cases high grade pTa, in 14.3% of cases pTis, and in 8.6% of cases pT1. Forty-three patients had recurrence, 13 reTURB patients (30.2%). In the patients who had a reTURB, 12 had recurrence (34.3%) against 31 without reTURB, (63.3%). After the first TURB, 45 patients (53.6%) had bladder instillation: 38 received BCG (45.2%) and 7 ametycin (8.3%). The main factor decreasing recurrence was BCG adjuvant therapy (HR=0.4 [0.2-0.9], P=0.02). The absence of reRTUV appeared to be a recurrence factor, but the result was not statistically significant (HR=1.4 [0.7-3], P=0.3). CONCLUSION reTURB confirms that residual tumor is often found. His interest in survival without recurrence remains to be proved by a prospective study with a larger number of patients. LEVEL OF EVIDENCE 3.
Collapse
Affiliation(s)
- B Branchu
- Service d'urologie, CHU de Reims, 51000 Reims, France.
| | - P Léon
- Service d'urologie, clinique Pasteur, 17200 Royan, France
| | | | - A Durlach
- Laboratoire d'anatomopathologie, CHU de Reims, 51000 Reims, France
| | - S Trigui
- Service d'urologie, Polyclinique Montier-la-celle, 10120 Saint-André-les-Vergers, France
| | - P Birembaut
- Laboratoire d'anatomopathologie, CHU de Reims, 51000 Reims, France
| | - S Larré
- Service d'urologie, CHU de Reims, 51000 Reims, France
| |
Collapse
|
10
|
Ancel J, Birembaut P, Dewolf M, Durlach A, Nawrocki-Raby B, Dalstein V, Delepine G, Blacher S, Deslée G, Gilles C, Polette M. Programmed Death-Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC. Cancers (Basel) 2019; 11:E1411. [PMID: 31546725 PMCID: PMC6826860 DOI: 10.3390/cancers11101411] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2019] [Revised: 09/16/2019] [Accepted: 09/19/2019] [Indexed: 12/25/2022] Open
Abstract
In non-metastatic non-small-cell lung cancer (NSCLC), outcomes remain poor. Adjuvant chemotherapies provide a limited improvement in disease-free survival. Recent exploratory studies on early-stage NSCLC show that immunotherapy given according to Programmed Death-Ligand 1 expression generates variable results, emphasizing a need to improve tumor characterization. We aimed to conjointly assess NSCLC, the expression of PD-L1, and epithelial-mesenchymal transition, frequently involved in tumor aggressiveness. 188 resected NSCLCs were analyzed. Among 188 patients with curatively resected NSCLC, 127 adenocarcinomas and 61 squamous cell carcinomas were stained for PD-L1 and vimentin expression. Overall survival has been compared regarding PD-L1 and vimentin statuses both separately and conjointly in Tumor Cancer Genome Atlas databases. PD-L1 and vimentin higher expressions were strongly associated (OR = 4.682, p < 0.0001). This co-expression occurred preferentially in tumors with lymph node invasion (p = 0.033). PD-L1 was significantly associated with high EMT features. NSCLC harboring both PD-L1high/vimentinhigh expressions were significantly associated with poor overall survival (p = 0.019). A higher co-expression of vimentin and PD-L1 was able to identify patients with worse outcomes. Similar to an important prognostic marker in NSCLC, this tandem marker needs to be further presented to anti-PD-L1 immunotherapies to improve outcome.
Collapse
Affiliation(s)
- Julien Ancel
- Inserm, Université de Reims Champagne Ardenne, P3Cell UMR-S1250, SFR CAP-SANTE, 51097 Reims, France
- Service de pneumologie, Hôpital Maison Blanche, CHU de Reims, 51092 Reims, France
| | - Philippe Birembaut
- Inserm, Université de Reims Champagne Ardenne, P3Cell UMR-S1250, SFR CAP-SANTE, 51097 Reims, France.
- Laboratoire de biopathologie, Hôpital Maison Blanche, CHU de Reims, 51092 Reims, France.
| | - Maxime Dewolf
- Service de pneumologie, Hôpital Maison Blanche, CHU de Reims, 51092 Reims, France
| | - Anne Durlach
- Inserm, Université de Reims Champagne Ardenne, P3Cell UMR-S1250, SFR CAP-SANTE, 51097 Reims, France
- Laboratoire de biopathologie, Hôpital Maison Blanche, CHU de Reims, 51092 Reims, France
| | - Béatrice Nawrocki-Raby
- Inserm, Université de Reims Champagne Ardenne, P3Cell UMR-S1250, SFR CAP-SANTE, 51097 Reims, France
| | - Véronique Dalstein
- Inserm, Université de Reims Champagne Ardenne, P3Cell UMR-S1250, SFR CAP-SANTE, 51097 Reims, France
- Laboratoire de biopathologie, Hôpital Maison Blanche, CHU de Reims, 51092 Reims, France
| | - Gonzague Delepine
- Inserm, Université de Reims Champagne Ardenne, P3Cell UMR-S1250, SFR CAP-SANTE, 51097 Reims, France
- Service de chirurgie cardio-vasculaire et thoracique, Hôpital Robert Debré, CHU de Reims, 51092 Reims, France
| | - Silvia Blacher
- Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Liège, 4000 Liège, Belgium
| | - Gaëtan Deslée
- Inserm, Université de Reims Champagne Ardenne, P3Cell UMR-S1250, SFR CAP-SANTE, 51097 Reims, France
- Service de pneumologie, Hôpital Maison Blanche, CHU de Reims, 51092 Reims, France
| | - Christine Gilles
- Laboratory of Tumor and Development Biology, GIGA-Cancer, University of Liège, 4000 Liège, Belgium
| | - Myriam Polette
- Inserm, Université de Reims Champagne Ardenne, P3Cell UMR-S1250, SFR CAP-SANTE, 51097 Reims, France
- Laboratoire de biopathologie, Hôpital Maison Blanche, CHU de Reims, 51092 Reims, France
| |
Collapse
|
11
|
Andries V, De Keuckelaere E, Staes K, Hochepied T, Taminau J, Lemeire K, Birembaut P, Berx G, van Roy F. A new mouse model to study the role of ectopic Nanos3 expression in cancer. BMC Cancer 2019; 19:598. [PMID: 31208373 PMCID: PMC6580527 DOI: 10.1186/s12885-019-5807-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2018] [Accepted: 06/06/2019] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND NANOS3 is a gene conserved throughout evolution. Despite the quite low conservation of Nanos sequences between different organisms and even between Nanos paralogs, their role in germ cell development is remarkably universal. Human Nanos3 expression is normally restricted to the gonads and the brain. However, ectopic activation of this gene has been detected in various human cancers. Until now, Nanos3 and other Nanos proteins have been studied almost exclusively in germ cell development. METHODS Transgenic mice were generated by targeted insertion of a human Nanos3 cDNA into the ROSA26 locus. The transgene could be spatiotemporally induced by Cre recombinase activity removing an upstream floxed STOP cassette. A lung tumor model with ectopic Nanos3 expression was based on the lung-specific activation of the reverse tetracycline transactivator gene, in combination with a tetO-CMV promoter controlling Cre expression. When doxycycline was provided to the mice, Cre was activated leading to deletion of TP53 alleles and activation of both oncogenic KRasG12D and Nanos3. Appropriate controls were foreseen. Tumors and tumor-derived cell cultures were analyzed in various ways. RESULTS We describe the successful generation of Nanos3LSL/- and Nanos3LSL/LSL mice in which an exogenous human NANOS3 gene can be activated in vivo upon Cre expression. These mice, in combination with different conditional and doxycycline-inducible Cre lines, allow the study of the role of ectopic Nanos3 expression in several cancer types. The Nanos3LSL mice were crossed with a non-small cell lung cancer (NSCLC) mouse model based on conditional expression of oncogenic KRas and homozygous loss of p53. This experiment demonstrated that ectopic expression of Nanos3 in the lungs has a significant negative effect on survival. Enhanced bronchiolar dysplasia was observed when Nanos3-expressing NSCLC mice were compared with control NSCLC mice. An allograft experiment, performed with cell cultures derived from primary lung tumors of control and Nanos3-expressing NSCLC mice, revealed lymph node metastasis in mice injected with Nanos3-expressing NSCLC cells. CONCLUSIONS A new mouse model was generated allowing examination of Nanos3-associated pathways and investigation of the influence of ectopic Nanos3 expression in various cancer types. This model might identify Nanos3 as an interesting target in cancer therapeutics.
Collapse
Affiliation(s)
- Vanessa Andries
- VIB-UGent Center for Inflammation Research (IRC), Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium.,Department of Biomedical Molecular Biology, Ghent University, Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium
| | - Evi De Keuckelaere
- VIB-UGent Center for Inflammation Research (IRC), Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium.,Department of Biomedical Molecular Biology, Ghent University, Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium.,Cancer Research Institute Ghent (CRIG), Ghent, Belgium
| | - Katrien Staes
- VIB-UGent Center for Inflammation Research (IRC), Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium.,Department of Biomedical Molecular Biology, Ghent University, Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium
| | - Tino Hochepied
- VIB-UGent Center for Inflammation Research (IRC), Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium.,Department of Biomedical Molecular Biology, Ghent University, Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium
| | - Joachim Taminau
- Department of Biomedical Molecular Biology, Ghent University, Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium.,Cancer Research Institute Ghent (CRIG), Ghent, Belgium
| | - Kelly Lemeire
- VIB-UGent Center for Inflammation Research (IRC), Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium.,Department of Biomedical Molecular Biology, Ghent University, Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium
| | - Philippe Birembaut
- INSERM UMRS 1250, Department of Biopathology, CHU Maison-Blanche, University Hospital of Reims & University of Reims Champagne-Ardenne, rue Cognacq-Jay 45, 51092, Reims, France
| | - Geert Berx
- Department of Biomedical Molecular Biology, Ghent University, Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium.,Cancer Research Institute Ghent (CRIG), Ghent, Belgium
| | - Frans van Roy
- VIB-UGent Center for Inflammation Research (IRC), Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium. .,Department of Biomedical Molecular Biology, Ghent University, Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium.
| |
Collapse
|
12
|
Gaydou V, Polette M, Gobinet C, Kileztky C, Angiboust JF, Birembaut P, Vuiblet V, Piot O. New insights into spectral histopathology: infrared-based scoring of tumour aggressiveness of squamous cell lung carcinomas. Chem Sci 2019; 10:4246-4258. [PMID: 31057753 PMCID: PMC6471539 DOI: 10.1039/c8sc04320e] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2018] [Accepted: 03/01/2019] [Indexed: 12/25/2022] Open
Abstract
Spectral histopathology, based on infrared interrogation of tissue sections, proved a promising tool for helping pathologists in characterizing histological structures in a quantitative and automatic manner.
Spectral histopathology, based on infrared interrogation of tissue sections, proved a promising tool for helping pathologists in characterizing histological structures in a quantitative and automatic manner. In cancer diagnosis, the use of chemometric methods permits establishing numerical models able to detect cancer cells and to characterize their tissular environment. In this study, we focused on exploiting multivariate infrared data to score the tumour aggressiveness in preneoplastic lesions and squamous cell lung carcinomas. These lesions present a wide range of aggressive phenotypes; it is also possible to encounter cases with various degrees of aggressiveness within the same lesion. Implementing an infrared-based approach for a more precise histological determination of the tumour aggressiveness should arouse interest among pathologists with direct benefits for patient care. In this study, the methodology was developed from a set of samples including all degrees of tumour aggressiveness and by constructing a chain of data processing steps for an automated analysis of tissues currently manipulated in routine histopathology.
Collapse
Affiliation(s)
- Vincent Gaydou
- BioSpecT Unit , EA 7506 , University of Reims Champagne-Ardenne , Pharmacy Department , 51 rue Cognacq-Jay , 51096 Reims , France .
| | - Myriam Polette
- INSERM UMR-S 1250 , University of Reims Champagne-Ardenne , 45, rue Cognacq-Jay , 51092 Reims , France.,Biopathology Laboratory , Centre Hospitalier et Universitaire de Reims , 45 Rue Cognacq-Jay , 51092 Reims , France
| | - Cyril Gobinet
- BioSpecT Unit , EA 7506 , University of Reims Champagne-Ardenne , Pharmacy Department , 51 rue Cognacq-Jay , 51096 Reims , France .
| | - Claire Kileztky
- INSERM UMR-S 1250 , University of Reims Champagne-Ardenne , 45, rue Cognacq-Jay , 51092 Reims , France
| | - Jean-François Angiboust
- BioSpecT Unit , EA 7506 , University of Reims Champagne-Ardenne , Pharmacy Department , 51 rue Cognacq-Jay , 51096 Reims , France .
| | - Philippe Birembaut
- INSERM UMR-S 1250 , University of Reims Champagne-Ardenne , 45, rue Cognacq-Jay , 51092 Reims , France.,Biopathology Laboratory , Centre Hospitalier et Universitaire de Reims , 45 Rue Cognacq-Jay , 51092 Reims , France
| | - Vincent Vuiblet
- BioSpecT Unit , EA 7506 , University of Reims Champagne-Ardenne , Pharmacy Department , 51 rue Cognacq-Jay , 51096 Reims , France . .,Biopathology Laboratory , Centre Hospitalier et Universitaire de Reims , 45 Rue Cognacq-Jay , 51092 Reims , France
| | - Olivier Piot
- BioSpecT Unit , EA 7506 , University of Reims Champagne-Ardenne , Pharmacy Department , 51 rue Cognacq-Jay , 51096 Reims , France . .,Platform of Cellular and Tissular Imaging (PICT) , University of Reims Champagne-Ardenne , 51 rue Cognacq-Jay , 51096 Reims , France
| |
Collapse
|
13
|
Perotin JM, Coraux C, Lagonotte E, Birembaut P, Delepine G, Polette M, Deslée G, Dormoy V. Alteration of primary cilia in COPD. Eur Respir J 2018; 52:13993003.00122-2018. [PMID: 29678947 DOI: 10.1183/13993003.00122-2018] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2018] [Accepted: 04/11/2018] [Indexed: 01/03/2023]
Affiliation(s)
- Jeanne-Marie Perotin
- Inserm U1250, University Hospital of Reims, Reims, France.,Dept of Respiratory Diseases, University Hospital of Reims, Reims, France
| | | | - Eymeric Lagonotte
- Inserm U1250, University Hospital of Reims, Reims, France.,University of Reims Champagne-Ardenne (URCA), SFR Cap-Santé, Reims, France
| | - Philippe Birembaut
- Inserm U1250, University Hospital of Reims, Reims, France.,University of Reims Champagne-Ardenne (URCA), SFR Cap-Santé, Reims, France.,Dept of Biopathology, University Hospital of Reims, Reims, France
| | - Gonzague Delepine
- Inserm U1250, University Hospital of Reims, Reims, France.,Dept of Cardio-Thoracic Surgery, University Hospital of Reims, Reims, France
| | - Myriam Polette
- Inserm U1250, University Hospital of Reims, Reims, France.,University of Reims Champagne-Ardenne (URCA), SFR Cap-Santé, Reims, France.,Dept of Biopathology, University Hospital of Reims, Reims, France
| | - Gaëtan Deslée
- Inserm U1250, University Hospital of Reims, Reims, France.,Dept of Respiratory Diseases, University Hospital of Reims, Reims, France.,University of Reims Champagne-Ardenne (URCA), SFR Cap-Santé, Reims, France
| | - Valérian Dormoy
- Inserm U1250, University Hospital of Reims, Reims, France.,University of Reims Champagne-Ardenne (URCA), SFR Cap-Santé, Reims, France
| |
Collapse
|
14
|
Boleto G, Perotin JM, Launois C, Uro-Coste E, Birembaut P, Dury S, Vallerand H, Lebargy F, Deslée G, Vella-Boucaud J. Nuclear protein in testis carcinoma of the mediastinum: a case report. J Med Case Rep 2017; 11:152. [PMID: 28595655 PMCID: PMC5465526 DOI: 10.1186/s13256-017-1328-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2017] [Accepted: 05/22/2017] [Indexed: 11/24/2022] Open
Abstract
Background Nuclear protein in testis carcinoma is a rare and very aggressive undifferentiated cancer which characteristically arises in the midline of the head, neck, and mediastinum. Case presentation We describe the case of a 46-year-old white woman admitted for superior vena cava syndrome revealing a mediastinal tumor. Pathological examination of specimens obtained by mediastinoscopy revealed an undifferentiated tumor with solid growth and positive immunoreactivity for p40 and negative immunoreactivity for cytokeratin markers. Immunohistochemical staining was positive for nuclear protein in testis, allowing the diagnosis of nuclear protein in testis midline carcinoma of the mediastinum. Conclusions We present a rare case of mediastinal nuclear protein in testis carcinoma with diagnosis based on nuclear protein in testis protein positivity and atypical immunohistochemical features including p40 positivity and anti-cytokeratin negativity. Physicians must remain aware of the possibility of nuclear protein in testis carcinoma especially in young patients with thoracic symptoms and suspicion of neoplasm.
Collapse
Affiliation(s)
- Gonçalo Boleto
- Department of Respiratory Medicine, Reims University Hospitals, Reims, France. .,Service de Pneumologie, Hôpital Maison Blanche, CHU Reims, 45 rue Cogncaq-Jay, 51092, Reims cedex, France.
| | - Jeanne-Marie Perotin
- Department of Respiratory Medicine, Reims University Hospitals, Reims, France.,INSERM UMR-S 903, Reims, France
| | - Claire Launois
- Department of Respiratory Medicine, Reims University Hospitals, Reims, France
| | - Emmanuelle Uro-Coste
- Department of Anatomy and Cytopathology, Cancer-Oncopole Institute, University of Toulouse, Toulouse, France.,INSERM UMR 1037, Cancer Research Centre, Toulouse, France
| | - Philippe Birembaut
- INSERM UMR-S 903, Reims, France.,Department of Pathology, Maison Blanche Hospital, Reims University Hospitals, Reims, France
| | - Sandra Dury
- Department of Respiratory Medicine, Reims University Hospitals, Reims, France.,EA 4683 Medical and Pharmacological University of Reims, Reims, France
| | - Hervé Vallerand
- Department of Respiratory Medicine, Reims University Hospitals, Reims, France
| | - François Lebargy
- Department of Respiratory Medicine, Reims University Hospitals, Reims, France.,EA 4683 Medical and Pharmacological University of Reims, Reims, France
| | - Gaëtan Deslée
- Department of Respiratory Medicine, Reims University Hospitals, Reims, France.,INSERM UMR-S 903, Reims, France
| | | |
Collapse
|
15
|
Nazarov PV, Muller A, Kaoma T, Nicot N, Maximo C, Birembaut P, Tran NL, Dittmar G, Vallar L. RNA sequencing and transcriptome arrays analyses show opposing results for alternative splicing in patient derived samples. BMC Genomics 2017; 18:443. [PMID: 28587590 PMCID: PMC5461714 DOI: 10.1186/s12864-017-3819-y] [Citation(s) in RCA: 56] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2017] [Accepted: 05/25/2017] [Indexed: 01/29/2023] Open
Abstract
Background RNA sequencing (RNA-seq) and microarrays are two transcriptomics techniques aimed at the quantification of transcribed genes and their isoforms. Here we compare the latest Affymetrix HTA 2.0 microarray with Illumina 2000 RNA-seq for the analysis of patient samples - normal lung epithelium tissue and squamous cell carcinoma lung tumours. Protein coding mRNAs and long non-coding RNAs (lncRNAs) were included in the study. Results Both platforms performed equally well for protein-coding RNAs, however the stochastic variability was higher for the sequencing data than for microarrays. This reduced the number of differentially expressed genes and genes with predictive potential for RNA-seq compared to microarray data. Analysis of this variability revealed a lack of reads for short and low abundant genes; lncRNAs, being shorter and less abundant RNAs, were found especially susceptible to this issue. A major difference between the two platforms was uncovered by analysis of alternatively spliced genes. Investigation of differential exon abundance showed insufficient reads for many exons and exon junctions in RNA-seq while the detection on the array platform was more stable. Nevertheless, we identified 207 genes which undergo alternative splicing and were consistently detected by both techniques. Conclusions Despite the fact that the results of gene expression analysis were highly consistent between Human Transcriptome Arrays and RNA-seq platforms, the analysis of alternative splicing produced discordant results. We concluded that modern microarrays can still outperform sequencing for standard analysis of gene expression in terms of reproducibility and cost. Electronic supplementary material The online version of this article (doi:10.1186/s12864-017-3819-y) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Petr V Nazarov
- Proteome and Genome Research Unit, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg.
| | - Arnaud Muller
- Proteome and Genome Research Unit, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Tony Kaoma
- Proteome and Genome Research Unit, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Nathalie Nicot
- Proteome and Genome Research Unit, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Cristina Maximo
- Proteome and Genome Research Unit, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | | | - Nhan L Tran
- Departments of Cancer Biology and Neurosurgery, Mayo Clinic Arizona, Phoenix, USA
| | - Gunnar Dittmar
- Proteome and Genome Research Unit, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - Laurent Vallar
- Proteome and Genome Research Unit, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg
| |
Collapse
|
16
|
Lacau St Guily J, Rousseau A, Baujat B, Périé S, Schultz P, Barry B, Dufour X, Malard O, Pretet JL, Clavel C, Birembaut P, Franceschi S. Oropharyngeal cancer prognosis by tumour HPV status in France: The multicentric Papillophar study. Oral Oncol 2017; 67:29-36. [PMID: 28351578 DOI: 10.1016/j.oraloncology.2017.01.012] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2016] [Revised: 01/03/2017] [Accepted: 01/27/2017] [Indexed: 01/21/2023]
Abstract
AIMS To evaluate the impact of human papillomavirus (HPV) status, tobacco smoking and initial treatment approach on progression-free survival (PFS) and overall survival (OS) for oropharyngeal cancer (OPC) in France, a country where smoking declines started late (1990s). METHODS 340 OPC patients (median age: 60years) from 14 French hospitals were followed up (median 26.7months). PCR-based positivity for both HPV DNA and E6/E7 mRNA was used to distinguish HPV-positive OPC (27.1%). Hospital-stratified hazard ratios (HR) and corresponding 95% confidence intervals (CI) were used to compare PFS and OS according to HPV and other prognostic factors in hospital-stratified unadjusted and multivariate models. The combined effect of HPV status with either smoking, stage, or initial treatment on PFS was also evaluated. RESULTS PFS in multivariate analysis was better in HPV-positive patients (HR=0.42; 95% CI: 0.24-0.73) and worse in older patients (HR for 5-year age increase=1.12) and those having had firstly radiotherapy (HR=1.86; 95% CI: 1.19-2.92) or induction chemotherapy (HR=1.73; 95% CI: 1.08-2.79) instead of upfront surgery. Findings for OS were similar. Loco-regional recurrences were less frequent in HPV-positive (10.5%) than HPV-negative patients (26.0%) but distant recurrences were similarly frequent. HPV status did not modify the influence of smoking or stage on PFS but the impossibility to perform upfront surgery may be more relevant for HPV-negative patients. CONCLUSIONS HPV-positive OPC patients fare better than HPV-negative OPC and may benefit from toxicity-sparing. Whether HPV-negative patients responded less well to radiation and chemotherapy because of more severe genomic damage or bulkier tumours is unclear.
Collapse
Affiliation(s)
- Jean Lacau St Guily
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Otolaryngology-Head and Neck Surgery, Tenon Hospital, 75020 Paris, France; Pierre-et-Marie Curie University - Sorbonne Universities, University Cancerology Institute UPMC, Paris, France.
| | - Alexandra Rousseau
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Clinical Pharmacology and Clinical Research Unit of East of Paris (URC-Est), Saint Antoine Hospital, 75012 Paris, France.
| | - Bertrand Baujat
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Otolaryngology-Head and Neck Surgery, Tenon Hospital, 75020 Paris, France; Pierre-et-Marie Curie University - Sorbonne Universities, University Cancerology Institute UPMC, Paris, France.
| | - Sophie Périé
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Otolaryngology-Head and Neck Surgery, Tenon Hospital, 75020 Paris, France; Pierre-et-Marie Curie University - Sorbonne Universities, University Cancerology Institute UPMC, Paris, France.
| | - Philippe Schultz
- Department of Otolaryngology-Head and Neck Surgery, Strasbourg University Hospital - Hautepierre, 67098 Strasbourg Cedex, France.
| | - Béatrix Barry
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Otolaryngology-Head and Neck Surgery, Bichat Hospital, and University-Paris 7, 75877 Paris Cedex 18, France.
| | - Xavier Dufour
- Department of Otolaryngology-Head and Neck Surgery, Poitiers University Hospital, 86021 Poitiers Cedex, France.
| | - Olivier Malard
- Department of Otolaryngology-Head and Neck Surgery, Nantes University Hospital - Hotel-Dieu, 44093 Nantes Cedex 1, France.
| | - Jean-Luc Pretet
- Franche-Comte University, COMUE UBFC, Besançon University Hospital - Jean Minjoz, 25030 Besançon Cedex, France; Inserm CIC 1431, 25030 Besançon Cedex, France.
| | - Christine Clavel
- INSERM UMR-S903, Reims University Hospital - Maison Blanche, 51092 Reims Cedex, France.
| | - Philippe Birembaut
- Laboratory of Biopathology, Reims University Hospital - Maison Blanche, Reims-Champagne-Ardenne University, 51092 Reims Cedex, France.
| | - Silvia Franceschi
- International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France.
| |
Collapse
|
17
|
Pouliquen DL, Nawrocki-Raby B, Nader J, Blandin S, Robard M, Birembaut P, Grégoire M. Evaluation of intracavitary administration of curcumin for the treatment of sarcomatoid mesothelioma. Oncotarget 2017; 8:57552-57573. [PMID: 28915695 PMCID: PMC5593667 DOI: 10.18632/oncotarget.15744] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2016] [Accepted: 02/06/2017] [Indexed: 12/15/2022] Open
Abstract
A rat model of sarcomatoid mesothelioma, mimicking some of the worst clinical conditions encountered, was established to evaluate the therapeutic potential of intracavitary curcumin administration. The M5-T1 cell line, selected from a collection established from F344 rats induced with asbestos, produces tumors within three weeks, with extended metastasis in normal tissues, after intraperitoneal inoculation in syngeneic rats. The optimal concentration/time conditions for killing M5-T1 cells with curcumin were first determined in vitro. Secondly, the potential of intraperitoneal curcumin administration to kill tumor cells in vivo was evaluated in tumor-bearing rats, in comparison with a reference epigenetic drug, SAHA. Both agents administered at days 21 and 26 after tumor challenge produced necrosis within the solid tumors at day 28. However, tumor tissue necrosis induced with curcumin was much more extensive than with SAHA, and was characterized by infiltration with mononuclear phagocytic cells. In contrast, tumor tissue treated with SAHA contained foci of resistant cells and was infiltrated by many isolated CD8+ cells. The treatment of tumor-bearing rats with 1.5 mg/kg curcumin on days 7, 9, 11 and 14 after tumor challenge dramatically reduced the mean total tumor mass at day 16. Clusters of CD8+ T lymphocytes were observed at the periphery of small residual tumor masses in the peritoneal cavity, which presented a significant reduction in mitotic index, IL6 and vimentin expression compared with tumors in untreated rats. These data open up interesting new prospects for the therapy of sarcomatoid mesothelioma with curcumin and its derivatives.
Collapse
Affiliation(s)
- Daniel L Pouliquen
- INSERM, UMR 1232, Nantes, France.,Université de Nantes, Nantes, France.,CNRS ERL, Nantes, France
| | - Béatrice Nawrocki-Raby
- INSERM, UMR-S 903, Reims, France.,Université de Reims Champagne-Ardenne, Reims, France.,SFR CAP-Santé, Reims, France
| | - Joëlle Nader
- INSERM, UMR 1232, Nantes, France.,Université de Nantes, Nantes, France.,CNRS ERL, Nantes, France
| | - Stéphanie Blandin
- Université de Nantes, Nantes, France.,Plate-forme MicroPICell, SFR François Bonamy, Nantes, France
| | - Myriam Robard
- Université de Nantes, Nantes, France.,Plate-forme MicroPICell, SFR François Bonamy, Nantes, France
| | - Philippe Birembaut
- INSERM, UMR-S 903, Reims, France.,Université de Reims Champagne-Ardenne, Reims, France.,SFR CAP-Santé, Reims, France.,Laboratory of Biopathology, CHU Reims, Reims, France
| | - Marc Grégoire
- INSERM, UMR 1232, Nantes, France.,Université de Nantes, Nantes, France.,CNRS ERL, Nantes, France
| |
Collapse
|
18
|
Lesage J, Suarez‐Carmona M, Neyrinck‐Leglantier D, Grelet S, Blacher S, Hunziker W, Birembaut P, Noël A, Nawrocki‐Raby B, Gilles C, Polette M. Zonula occludens‐1/NF‐κB/CXCL8: a new regulatory axis for tumor angiogenesis. FASEB J 2017; 31:1678-1688. [DOI: 10.1096/fj.201600890r] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2017] [Accepted: 01/03/2017] [Indexed: 01/18/2023]
Affiliation(s)
- Julien Lesage
- INSERM, Unité Mixte de Recherche–S 903, Structure Fédérative de Recherche Champagne‐Ardennes Picardie Santé (SFR CAP)University of Reims Champagne‐Ardenne Reims France
| | - Meggy Suarez‐Carmona
- Laboratory of Tumor and Development Biology, Grappe Interdisciplinaire de Génoprotéomique Appliquée (GIGA)‐CancerUniversity of Liège Liège Belgium
| | - Deborah Neyrinck‐Leglantier
- INSERM, Unité Mixte de Recherche–S 903, Structure Fédérative de Recherche Champagne‐Ardennes Picardie Santé (SFR CAP)University of Reims Champagne‐Ardenne Reims France
| | - Simon Grelet
- Department of Biochemistry and Molecular BiologyMedical University of South Carolina Charleston South Carolina USA
| | - Silvia Blacher
- Laboratory of Tumor and Development Biology, Grappe Interdisciplinaire de Génoprotéomique Appliquée (GIGA)‐CancerUniversity of Liège Liège Belgium
| | - Walter Hunziker
- Epithelial Cell Biology LaboratoryInstitute of Molecular and Cell Biology Singapore Singapore
| | - Philippe Birembaut
- INSERM, Unité Mixte de Recherche–S 903, Structure Fédérative de Recherche Champagne‐Ardennes Picardie Santé (SFR CAP)University of Reims Champagne‐Ardenne Reims France
- Laboratory of BiopathologyCentres Hospitaliers Universitaires Reims France
| | - Agnes Noël
- Laboratory of Tumor and Development Biology, Grappe Interdisciplinaire de Génoprotéomique Appliquée (GIGA)‐CancerUniversity of Liège Liège Belgium
| | - Béatrice Nawrocki‐Raby
- INSERM, Unité Mixte de Recherche–S 903, Structure Fédérative de Recherche Champagne‐Ardennes Picardie Santé (SFR CAP)University of Reims Champagne‐Ardenne Reims France
| | - Christine Gilles
- Laboratory of Tumor and Development Biology, Grappe Interdisciplinaire de Génoprotéomique Appliquée (GIGA)‐CancerUniversity of Liège Liège Belgium
| | - Myriam Polette
- INSERM, Unité Mixte de Recherche–S 903, Structure Fédérative de Recherche Champagne‐Ardennes Picardie Santé (SFR CAP)University of Reims Champagne‐Ardenne Reims France
- Laboratory of BiopathologyCentres Hospitaliers Universitaires Reims France
| |
Collapse
|
19
|
Vuiblet V, Fere M, Bankole E, Wynckel A, Gobinet C, Birembaut P, Piot O, Rieu P. Raman-based detection of hydroxyethyl starch in kidney allograft biopsies as a potential marker of allograft quality in kidney transplant recipients. Sci Rep 2016; 6:33045. [PMID: 27608775 PMCID: PMC5016807 DOI: 10.1038/srep33045] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2016] [Accepted: 07/01/2016] [Indexed: 01/25/2023] Open
Abstract
In brain-dead donor resuscitation, hydroxyethyl starch (HES) use has been associated with presence of osmotic-nephrosis-like lesions in kidney transplant recipients. Our aim was to determine whether the presence of HES in protocol renal graft biopsies at three months (M3) after transplantation is associated with renal graft quality. According to the HES administered to the donor during the procurement procedure, two groups of patients were defined according graft exposition to HES: HES group, (N = 20) and control group (N = 6). Detection and relative quantification of HES was performed by Raman spectroscopy microimaging on M3 protocol renal graft biopsies. Statistical analyses were used to investigate the association between Raman data and graft characteristics. HES spectral signal was revealed negative in the control group, whereas it was positive in 40% of biopsies from the HES group. In the HES group, a stronger HES signal was associated with a lower risk of graft failure measured by the Kidney Donor Risk Index (KDRI) and was correlated with the allograft kidney function. Thus, HES accumulation in donor kidney, as probed by Raman biophotonic technique, is correlated with the quality of donor kidney and consequently the graft renal function and graft survival.
Collapse
Affiliation(s)
- Vincent Vuiblet
- UMR CNRS 7369 MEDyC, Université de Reims Champagne-Ardennes, Reims, France.,Nephrology division, Maison Blanche University Hospital, Reims, France.,Biopathology Laboratory, Maison Blanche University Hospital, Reims, France
| | - Michael Fere
- UMR CNRS 7369 MEDyC, Université de Reims Champagne-Ardennes, Reims, France
| | - Ezechiel Bankole
- Department of Anesthesia, Maison Blanche University Hospital, Reims, France
| | - Alain Wynckel
- Nephrology division, Maison Blanche University Hospital, Reims, France
| | - Cyril Gobinet
- UMR CNRS 7369 MEDyC, Université de Reims Champagne-Ardennes, Reims, France
| | - Philippe Birembaut
- Biopathology Laboratory, Maison Blanche University Hospital, Reims, France
| | - Olivier Piot
- UMR CNRS 7369 MEDyC, Université de Reims Champagne-Ardennes, Reims, France.,PICT (Cellular and Tissular Imaging Platform), Université de Reims Champagne- Ardenne, Reims, France
| | - Philippe Rieu
- UMR CNRS 7369 MEDyC, Université de Reims Champagne-Ardennes, Reims, France.,Nephrology division, Maison Blanche University Hospital, Reims, France
| |
Collapse
|
20
|
Gaydou V, Polette M, Gobinet C, Kileztky C, Angiboust JF, Manfait M, Birembaut P, Piot O. Vibrational Analysis of Lung Tumor Cell Lines: Implementation of an Invasiveness Scale Based on the Cell Infrared Signatures. Anal Chem 2016; 88:8459-67. [DOI: 10.1021/acs.analchem.6b00590] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Vincent Gaydou
- Equipe MéDIAN—Biophotonique
et Technologies pour la Santé Université de Reims Champagne-Ardenne,
UFR de Pharmacie, 51 rue Cognacq-Jay, 51096 Reims, France
- CNRS UMR 7369 MEDyC,
SFR Cap-Santé, 51 rue Cognacq-Jay, 51096 Reims, France
| | - Myriam Polette
- INSERM
UMR-S 903, SFR CAP-Santé, University of Reims-Champagne-Ardenne, 45, rue Cognacq-Jay, 51092 Reims, France
- Biopathology
Laboratory, Centre Hospitalier et Universitaire de Reims, 45 Rue Cognacq-Jay, 51092 Reims, France
- Platform
of Cellular and Tissular Imaging (PICT), Université de Reims Champagne-Ardenne, 51 rue Cognacq-Jay, 51096 Reims, France
| | - Cyril Gobinet
- Equipe MéDIAN—Biophotonique
et Technologies pour la Santé Université de Reims Champagne-Ardenne,
UFR de Pharmacie, 51 rue Cognacq-Jay, 51096 Reims, France
- CNRS UMR 7369 MEDyC,
SFR Cap-Santé, 51 rue Cognacq-Jay, 51096 Reims, France
- Platform
of Cellular and Tissular Imaging (PICT), Université de Reims Champagne-Ardenne, 51 rue Cognacq-Jay, 51096 Reims, France
| | - Claire Kileztky
- INSERM
UMR-S 903, SFR CAP-Santé, University of Reims-Champagne-Ardenne, 45, rue Cognacq-Jay, 51092 Reims, France
- Biopathology
Laboratory, Centre Hospitalier et Universitaire de Reims, 45 Rue Cognacq-Jay, 51092 Reims, France
| | - Jean-François Angiboust
- Equipe MéDIAN—Biophotonique
et Technologies pour la Santé Université de Reims Champagne-Ardenne,
UFR de Pharmacie, 51 rue Cognacq-Jay, 51096 Reims, France
- CNRS UMR 7369 MEDyC,
SFR Cap-Santé, 51 rue Cognacq-Jay, 51096 Reims, France
| | - Michel Manfait
- Equipe MéDIAN—Biophotonique
et Technologies pour la Santé Université de Reims Champagne-Ardenne,
UFR de Pharmacie, 51 rue Cognacq-Jay, 51096 Reims, France
- CNRS UMR 7369 MEDyC,
SFR Cap-Santé, 51 rue Cognacq-Jay, 51096 Reims, France
| | - Philippe Birembaut
- INSERM
UMR-S 903, SFR CAP-Santé, University of Reims-Champagne-Ardenne, 45, rue Cognacq-Jay, 51092 Reims, France
- Biopathology
Laboratory, Centre Hospitalier et Universitaire de Reims, 45 Rue Cognacq-Jay, 51092 Reims, France
| | - Olivier Piot
- Equipe MéDIAN—Biophotonique
et Technologies pour la Santé Université de Reims Champagne-Ardenne,
UFR de Pharmacie, 51 rue Cognacq-Jay, 51096 Reims, France
- CNRS UMR 7369 MEDyC,
SFR Cap-Santé, 51 rue Cognacq-Jay, 51096 Reims, France
- Platform
of Cellular and Tissular Imaging (PICT), Université de Reims Champagne-Ardenne, 51 rue Cognacq-Jay, 51096 Reims, France
| |
Collapse
|
21
|
Liné A, Sanchez J, Jayyosi L, Birembaut P, Ohl X, Poli-Mérol ML, François C. Papillary endothelial hyperplasia (Masson's tumor) in children. ANN CHIR PLAST ESTH 2016; 62:232-237. [PMID: 27346753 DOI: 10.1016/j.anplas.2016.05.010] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2016] [Accepted: 05/23/2016] [Indexed: 12/19/2022]
Abstract
The intravascular papillary endothelial hyperplasia (IPEH/Masson's tumor) is a rare benign tumor of the skin and subcutaneous vessels. We report, in four pediatric cases, clinical presentation, care (diagnostic and surgical) of Masson's tumor in children. Two boys (two years) and two girls (four and six years) showed a pain subcutaneous tumor (one to five centimeters). They were in the transverse abdominal muscle, between two metatarsals, at the front of thigh and in the axilla. Imaging performed (MRI, Doppler ultrasound) evoked either a hematoma, a lymphangioma or hemangioma. The indication for removal was selected from pain and/or parental concern. The diagnosis was histologically. A lesion persisted in residual form (incomplete initial resection), and is currently not scalable for eleven years. DISCUSSION This tumor is characterized by excessive proliferation and papillary endothelial cells in the vessels, following a thrombotic event. It is found mainly in adults (no specific age), and preferentially localizes in the face and limbs. The clinical differential diagnosis of this tumor is angiosarcoma. The imagery has not allowed in our series to diagnose but still essential to eliminate differential diagnoses. Only surgical excision with histological examination can differentiate. Our study emphasizes the possibility of pediatric cases with two cases of unusual locations (abdominal and axilla). Clinical presentations we met, now lead us to direct our histologist looking for a Masson tumor in any child with a subcutaneous tumor and/or intramuscular pain, sudden onset, and vascular appearance (after excluding an arteriovenous malformation).
Collapse
Affiliation(s)
- A Liné
- CHU de Reims, American Memorial Hospital, Chirurgie pédiatrique, 47, rue Cognacq-Jay, 51100 Reims, France
| | - J Sanchez
- CHU de Reims, Hôpital Maison-Blanche, Chirurgie plastique reconstructrice et esthétique, 45, rue Cognacq-Jay, 51100 Reims, France
| | - L Jayyosi
- CHU de Reims, Hôpital Maison-Blanche, Chirurgie plastique reconstructrice et esthétique, 45, rue Cognacq-Jay, 51100 Reims, France
| | - P Birembaut
- Hôpital Maison-blanche, Pol BOUIN, Laboratoire de Biopathologie, 45, rue Cognacq-Jay, 51100 Reims, France
| | - X Ohl
- CHU de Reims, Hôpital Maison-Blanche, Chirurgie orthopédique, 45, rue Cognacq-Jay, 51100 Reims, France
| | - M-L Poli-Mérol
- CHU de Reims, American Memorial Hospital, Chirurgie pédiatrique, 47, rue Cognacq-Jay, 51100 Reims, France
| | - C François
- CHU de Reims, American Memorial Hospital, Chirurgie pédiatrique, 47, rue Cognacq-Jay, 51100 Reims, France; CHU de Reims, Hôpital Maison-Blanche, Chirurgie plastique reconstructrice et esthétique, 45, rue Cognacq-Jay, 51100 Reims, France; Université de Reims Champagne-Ardenne, EA 3801, 51, rue Cognacq-Jay, 51100 Reims, France.
| |
Collapse
|
22
|
Vuiblet V, Fere M, Gobinet C, Birembaut P, Piot O, Rieu P. Renal Graft Fibrosis and Inflammation Quantification by an Automated Fourier-Transform Infrared Imaging Technique. J Am Soc Nephrol 2015; 27:2382-91. [PMID: 26683669 DOI: 10.1681/asn.2015050601] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2015] [Accepted: 11/01/2015] [Indexed: 01/05/2023] Open
Abstract
Renal interstitial fibrosis and interstitial active inflammation are the main histologic features of renal allograft biopsy specimens. Fibrosis is currently assessed by semiquantitative subjective analysis, and color image analysis has been developed to improve the reliability and repeatability of this evaluation. However, these techniques fail to distinguish fibrosis from constitutive collagen or active inflammation. We developed an automatic, reproducible Fourier-transform infrared (FTIR) imaging-based technique for simultaneous quantification of fibrosis and inflammation in renal allograft biopsy specimens. We generated and validated a classification model using 49 renal biopsy specimens and subsequently tested the robustness of this classification algorithm on 166 renal grafts. Finally, we explored the clinical relevance of fibrosis quantification using FTIR imaging by comparing results with renal function at 3 months after transplantation (M3) and the variation of renal function between M3 and M12. We showed excellent robustness for fibrosis and inflammation classification, with >90% of renal biopsy specimens adequately classified by FTIR imaging. Finally, fibrosis quantification by FTIR imaging correlated with renal function at M3, and the variation in fibrosis between M3 and M12 correlated well with the variation in renal function over the same period. This study shows that FTIR-based analysis of renal graft biopsy specimens is a reproducible and reliable label-free technique for quantifying fibrosis and active inflammation. This technique seems to be more relevant than digital image analysis and promising for both research studies and routine clinical practice.
Collapse
Affiliation(s)
- Vincent Vuiblet
- Matrice Extracellulaire et Dynamique Cellulaire Unit, Centre National pour la Recherche Scientifique, Unité Mixte de Recherche 7369, and Nephrology and Renal Transplantation Department and Biopathology Laboratory, Centre Hospitalier et Universitaire de Reims, Reims, France
| | - Michael Fere
- Matrice Extracellulaire et Dynamique Cellulaire Unit, Centre National pour la Recherche Scientifique, Unité Mixte de Recherche 7369, and
| | - Cyril Gobinet
- Matrice Extracellulaire et Dynamique Cellulaire Unit, Centre National pour la Recherche Scientifique, Unité Mixte de Recherche 7369, and
| | - Philippe Birembaut
- Biopathology Laboratory, Centre Hospitalier et Universitaire de Reims, Reims, France
| | - Olivier Piot
- Matrice Extracellulaire et Dynamique Cellulaire Unit, Centre National pour la Recherche Scientifique, Unité Mixte de Recherche 7369, and Cellular and Tissular Imaging Platform, Université de Reims Champagne-Ardenne, Reims, France; and
| | - Philippe Rieu
- Matrice Extracellulaire et Dynamique Cellulaire Unit, Centre National pour la Recherche Scientifique, Unité Mixte de Recherche 7369, and Nephrology and Renal Transplantation Department and
| |
Collapse
|
23
|
Franceschi S, Combes JD, Dalstein V, Caudroy S, Clifford G, Gheit T, Tommasino M, Clavel C, Lacau St Guily J, Birembaut P. Deep brush-based cytology in tonsils resected for benign diseases. Int J Cancer 2015; 137:2994-9. [PMID: 26111735 DOI: 10.1002/ijc.29660] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2015] [Accepted: 06/22/2015] [Indexed: 03/25/2024]
Abstract
A fraction of oropharyngeal cancer (OPC), especially in the tonsil, is caused by human papillomavirus (HPV), mainly HPV16. Noninvasive diagnostic methods to detect precancerous lesions in the tonsil would be useful, e.g., liquid-based cytology (LBC). However, ill-characterized precancerous lesions may be hidden in the depth of the tonsillar crypts. We therefore conducted a study on HPV and tonsillar precancerous lesions to evaluate, among other things, the utility of LBC obtained by deep brushing of the resected tonsils. Two hundred non-paediatric patients (mean age: 30.3 years) who underwent tonsillectomy for infection-related conditions (69%) or other conditions (mainly obstructive sleep apnoea, 31%) were included. An ultra-sensitive Luminex bead-based platform was used to test for the DNA of 21 mucosal HPV types; 56% of slides were unsatisfactory due to low number of squamous epithelial cells or the masking effect of a large number of lymphocytes. Three patients (1.5%; 95% CI: 0.5-4.3) showed suspicious cytological findings (atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion, ASC-H) while 3 others were HPV-positive (2 for HPV16 and 1 for HPV39). None of the ASC-H patients and HPV-positive patients showed dysplasia at histological examination. The rarity of HPV infection in the tonsil conflicts with the relatively frequent detection of the virus in the mouth. In conclusion, aggressive deep brushing of tonsils, while hardly applicable in vivo, is unlikely to be a reliable method to detect precancerous lesions. The absence of OPC screening modalities places the priority on multi-purpose primary prevention strategies, i.e., HPV vaccination and reduction of smoking and drinking.
Collapse
Affiliation(s)
- Silvia Franceschi
- International Agency for Research on Cancer, 69372 Lyon cedex 08, France
| | - Jean-Damien Combes
- International Agency for Research on Cancer, 69372 Lyon cedex 08, France
| | - Véronique Dalstein
- CHU Reims, Hôpital Maison Blanche, Laboratoire Pol Bouin Histologie - Cytologie - Biologie Cellulaire, Reims, F-51092, France
- INSERM, UMR-S 903, Reims, F-51092 France, Université de Reims Champagne-Ardenne, Faculté de Médecine, Reims, F-51095 France
| | - Stéphanie Caudroy
- CHU Reims, Hôpital Maison Blanche, Laboratoire Pol Bouin Histologie - Cytologie - Biologie Cellulaire, Reims, F-51092, France
- INSERM, UMR-S 903, Reims, F-51092 France, Université de Reims Champagne-Ardenne, Faculté de Médecine, Reims, F-51095 France
| | - Gary Clifford
- International Agency for Research on Cancer, 69372 Lyon cedex 08, France
| | - Tarik Gheit
- International Agency for Research on Cancer, 69372 Lyon cedex 08, France
| | - Massimo Tommasino
- International Agency for Research on Cancer, 69372 Lyon cedex 08, France
| | - Christine Clavel
- CHU Reims, Hôpital Maison Blanche, Laboratoire Pol Bouin Histologie - Cytologie - Biologie Cellulaire, Reims, F-51092, France
- INSERM, UMR-S 903, Reims, F-51092 France, Université de Reims Champagne-Ardenne, Faculté de Médecine, Reims, F-51095 France
| | - Jean Lacau St Guily
- Department of Otorhinolaryngology and Head and Neck Surgery, Faculty of Medicine-Pierre Et Marie Curie University-Paris VI and Tenon Hospital, Assistance Publique Hôpitaux De Paris, France
| | - Philippe Birembaut
- CHU Reims, Hôpital Maison Blanche, Laboratoire Pol Bouin Histologie - Cytologie - Biologie Cellulaire, Reims, F-51092, France
- INSERM, UMR-S 903, Reims, F-51092 France, Université de Reims Champagne-Ardenne, Faculté de Médecine, Reims, F-51095 France
| |
Collapse
|
24
|
Gaydou VD, Polette M, Gobinet C, Kileztky C, Manfait M, Birembaut P, Piot O. Abstract 212: Infrared spectral diagnosis for predictive cancer medicine: application to the early diagnosis and prognosis of preinvasive bronchial intraepithelial lesions. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-212] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This study concerns the development of a new imaging diagnostic tool for bronchial cancer. This malignancy is a wide-spread cancer in the world, with an increasing incidence. Our objective is to assess the potential of infrared (IR) spectroscopy in the early diagnosis of the bronchial cancer. Our approach is divided into two steps: the first issue aims at highlighting specific spectroscopic markers of the bronchial cancer permitting to detect unambiguously the presence of cancer cells. The second step relies on establishing a chemometric model able to estimate the tumor invasivity of these malignant cells
For our approach, we used 4 different bronchial cellular lines displaying different in vitro invasive properties assessed by a modified Boyden chamber assay : the non invasive cell line 16HBE used as a control, the moderate invasive cell line Beas2B and the two highly invasive cell lines BZR and BZRT33. Four samples of each cell line were cultured and embedded in paraffin wax. Slices of 10 μm were prepared on CaF2 windows suitable for IR measurements. The infrared acquisitions were performed with an imager (Bruker, Germany) equipped with a Focal Plane Array detector allowing to image large tissue areas with a spatial resolution of a few micrometers.
The IR spectra were processed using chemometric and statistical multivariate treatments. A first stage permitted to correct spectral interferences originated from the paraffin and optical effects. Then, supervised models were established by means of PLS-DA (Partial Least Square Discriminant Analysis) method. A first model, based on sparse-PLS method, was optimized to highlight spectroscopic markers specific of the normal and cancerous states; this model has proved effective in terms of sensibility (96%) and specificity (90%). Based on these promising results, the study will be pursued by the analysis of tissue samples from biopsies and tumor samples. Subsequently, the next investigation will rely on the construction of a second model to model and quantify the aggressiveness level of the cell lines.
Citation Format: Vincent D. Gaydou, Myriame Polette, Cyril Gobinet, Claire Kileztky, Michel Manfait, Philippe Birembaut, Olivier Piot. Infrared spectral diagnosis for predictive cancer medicine: application to the early diagnosis and prognosis of preinvasive bronchial intraepithelial lesions. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 212. doi:10.1158/1538-7445.AM2015-212
Collapse
Affiliation(s)
- Vincent D. Gaydou
- 1CNRS UMR7369, Matrice Extracellulaire et Dynamique Cellulaire, MEDyC, Reims, France
| | - Myriame Polette
- 2INSERM UMR-S 903, SFR CAP-Santé, University of Reims-Champagne-Ardenne, Reims, France
| | - Cyril Gobinet
- 1CNRS UMR7369, Matrice Extracellulaire et Dynamique Cellulaire, MEDyC, Reims, France
| | - Claire Kileztky
- 2INSERM UMR-S 903, SFR CAP-Santé, University of Reims-Champagne-Ardenne, Reims, France
| | - Michel Manfait
- 1CNRS UMR7369, Matrice Extracellulaire et Dynamique Cellulaire, MEDyC, Reims, France
| | - Philippe Birembaut
- 2INSERM UMR-S 903, SFR CAP-Santé, University of Reims-Champagne-Ardenne, Reims, France
| | - Olivier Piot
- 1CNRS UMR7369, Matrice Extracellulaire et Dynamique Cellulaire, MEDyC, Reims, France
| |
Collapse
|
25
|
Grelet S, Andries V, Polette M, Gilles C, Staes K, Martin AP, Kileztky C, Terryn C, Dalstein V, Cheng CW, Shen CY, Birembaut P, Van Roy F, Nawrocki-Raby B. The human NANOS3 gene contributes to lung tumour invasion by inducing epithelial-mesenchymal transition. J Pathol 2015; 237:25-37. [PMID: 25904364 DOI: 10.1002/path.4549] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2014] [Revised: 03/30/2015] [Accepted: 04/17/2015] [Indexed: 01/01/2023]
Abstract
We have explored the role of the human NANOS3 gene in lung tumour progression. We show that NANOS3 is over-expressed by invasive lung cancer cells and is a prognostic marker for non-small cell lung carcinomas (NSCLCs). NANOS3 gene expression is restricted in testis and brain and is regulated by epigenetic events. It is up-regulated in cultured cells undergoing epithelial - mesenchymal transition (EMT). NANOS3 over-expression in human NSCLC cell lines enhances their invasiveness by up-regulating EMT, whereas its silencing induces mesenchymal - epithelial transition. NANOS3 represses E-cadherin at the transcriptional level and up-regulates vimentin post-transcriptionally. Also, we show that NANOS3 binds mRNAs encoding vimentin and regulates the length of their poly(A) tail. Finally, NANOS3 can also protect vimentin mRNA from microRNA-mediated repression. We thus demonstrate a role for NANOS3 in the acquisition of invasiveness by human lung tumour cells and propose a new mechanism of post-transcriptional regulation of EMT.
Collapse
Affiliation(s)
- Simon Grelet
- INSERM UMR-S 903, SFR CAP-Santé, University of Reims Champagne-Ardenne, France
| | - Vanessa Andries
- Department of Biomedical Molecular Biology, Ghent University, Belgium.,Molecular Cell Biology Unit, Inflammation Research Centre, Ghent, Belgium
| | - Myriam Polette
- INSERM UMR-S 903, SFR CAP-Santé, University of Reims Champagne-Ardenne, France.,Laboratory of Histology, CHU Reims, France
| | - Christine Gilles
- Laboratory of Developmental and Tumour Biology, GIGA-Cancer, University of Liège, Belgium
| | - Katrien Staes
- Department of Biomedical Molecular Biology, Ghent University, Belgium.,Molecular Cell Biology Unit, Inflammation Research Centre, Ghent, Belgium
| | | | - Claire Kileztky
- INSERM UMR-S 903, SFR CAP-Santé, University of Reims Champagne-Ardenne, France
| | - Christine Terryn
- Plateforme Imagerie Cellulaire et Tissulaire, University of Reims Champagne-Ardenne, France
| | - Véronique Dalstein
- INSERM UMR-S 903, SFR CAP-Santé, University of Reims Champagne-Ardenne, France.,Laboratory of Histology, CHU Reims, France
| | - Chun-Wen Cheng
- Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
| | - Chen-Yang Shen
- Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
| | - Philippe Birembaut
- INSERM UMR-S 903, SFR CAP-Santé, University of Reims Champagne-Ardenne, France.,Laboratory of Histology, CHU Reims, France
| | - Frans Van Roy
- Department of Biomedical Molecular Biology, Ghent University, Belgium.,Molecular Cell Biology Unit, Inflammation Research Centre, Ghent, Belgium
| | | |
Collapse
|
26
|
Suarez-Carmona M, Bourcy M, Lesage J, Leroi N, Syne L, Blacher S, Hubert P, Erpicum C, Foidart JM, Delvenne P, Birembaut P, Noël A, Polette M, Gilles C. Soluble factors regulated by epithelial-mesenchymal transition mediate tumour angiogenesis and myeloid cell recruitment. J Pathol 2015; 236:491-504. [PMID: 25880038 DOI: 10.1002/path.4546] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2014] [Revised: 03/18/2015] [Accepted: 04/13/2015] [Indexed: 01/13/2023]
Abstract
Epithelial-mesenchymal transition (EMT) programmes provide cancer cells with invasive and survival capacities that might favour metastatic dissemination. Whilst signalling cascades triggering EMT have been extensively studied, the impact of EMT on the crosstalk between tumour cells and the tumour microenvironment remains elusive. We aimed to identify EMT-regulated soluble factors that facilitate the recruitment of host cells in the tumour. Our findings indicate that EMT phenotypes relate to the induction of a panel of secreted mediators, namely IL-8, IL-6, sICAM-1, PAI-1 and GM-CSF, and implicate the EMT-transcription factor Snail as a regulator of this process. We further show that EMT-derived soluble factors are pro-angiogenic in vivo (in the mouse ear sponge assay), ex vivo (in the rat aortic ring assay) and in vitro (in a chemotaxis assay). Additionally, conditioned medium from EMT-positive cells stimulates the recruitment of myeloid cells. In a bank of 40 triple-negative breast cancers, tumours presenting features of EMT were significantly more angiogenic and infiltrated by a higher quantity of myeloid cells compared to tumours with little or no EMT. Taken together, our results show that EMT programmes trigger the expression of soluble mediators in cancer cells that stimulate angiogenesis and recruit myeloid cells in vivo, which might in turn favour cancer spread.
Collapse
Affiliation(s)
- Meggy Suarez-Carmona
- Laboratory of Tumour and Development Biology (LBTD), GIGA-Cancer, Liège, Belgium.,Laboratory of Experimental Pathology (LEP), GIGA-Cancer, Liège, Belgium
| | - Morgane Bourcy
- Laboratory of Tumour and Development Biology (LBTD), GIGA-Cancer, Liège, Belgium
| | - Julien Lesage
- INSERM UMR-S 903, Laboratoire Pol Bouin, University of Reims, France
| | - Natacha Leroi
- Laboratory of Tumour and Development Biology (LBTD), GIGA-Cancer, Liège, Belgium
| | - Laïdya Syne
- Laboratory of Tumour and Development Biology (LBTD), GIGA-Cancer, Liège, Belgium
| | - Silvia Blacher
- Laboratory of Tumour and Development Biology (LBTD), GIGA-Cancer, Liège, Belgium
| | - Pascale Hubert
- Laboratory of Experimental Pathology (LEP), GIGA-Cancer, Liège, Belgium
| | - Charlotte Erpicum
- Laboratory of Experimental Pathology (LEP), GIGA-Cancer, Liège, Belgium
| | - Jean-Michel Foidart
- Laboratory of Tumour and Development Biology (LBTD), GIGA-Cancer, Liège, Belgium
| | - Philippe Delvenne
- Laboratory of Experimental Pathology (LEP), GIGA-Cancer, Liège, Belgium
| | | | - Agnès Noël
- Laboratory of Tumour and Development Biology (LBTD), GIGA-Cancer, Liège, Belgium
| | - Myriam Polette
- INSERM UMR-S 903, Laboratoire Pol Bouin, University of Reims, France
| | - Christine Gilles
- Laboratory of Tumour and Development Biology (LBTD), GIGA-Cancer, Liège, Belgium
| |
Collapse
|
27
|
Gohy ST, Hupin C, Fregimilicka C, Detry BR, Bouzin C, Gaide Chevronay H, Lecocq M, Weynand B, Ladjemi MZ, Pierreux CE, Birembaut P, Polette M, Pilette C. Imprinting of the COPD airway epithelium for dedifferentiation and mesenchymal transition. Eur Respir J 2015; 45:1258-72. [DOI: 10.1183/09031936.00135814] [Citation(s) in RCA: 103] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2014] [Accepted: 10/24/2014] [Indexed: 02/03/2023]
Abstract
In chronic obstructive pulmonary disease (COPD), epithelial changes and subepithelial fibrosis are salient features in conducting airways. Epithelial-to-mesenchymal transition (EMT) has been recently suggested in COPD, but the mechanisms and relationship to peribronchial fibrosis remain unclear. We hypothesised that de-differentiation of the COPD respiratory epithelium through EMT could participate in airway fibrosis and thereby, in airway obstruction.Surgical lung tissue and primary broncho-epithelial cultures (in air–liquid interface (ALI)) from 104 patients were assessed for EMT markers. Cell cultures were also assayed for mesenchymal features and for the role of transforming growth factor (TGF)-β1.The bronchial epithelium from COPD patients showed increased vimentin and decreased ZO-1 and E-cadherin expression. Increased vimentin expression correlated with basement membrane thickening and airflow limitation. ALI broncho-epithelial cells from COPD patients also displayed EMT phenotype in up to 2 weeks of culture, were more spindle shaped and released more fibronectin. Targeting TGF-β1 during ALI differentiation prevented vimentin induction and fibronectin release.In COPD, the airway epithelium displays features of de-differentiation towards mesenchymal cells, which correlate with peribronchial fibrosis and airflow limitation, and which are partly due to a TGF-β1-driven epithelial reprogramming.
Collapse
|
28
|
Medjber K, Freidja ML, Grelet S, Lorenzato M, Maouche K, Nawrocki-Raby B, Birembaut P, Polette M, Tournier JM. Role of nicotinic acetylcholine receptors in cell proliferation and tumour invasion in broncho-pulmonary carcinomas. Lung Cancer 2015; 87:258-64. [DOI: 10.1016/j.lungcan.2015.01.001] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2014] [Revised: 12/19/2014] [Accepted: 01/02/2015] [Indexed: 11/29/2022]
|
29
|
Lesage J, Grelet S, Nawrocki-Raby B, Birembaut P, Gilles C, Polette M. Régulation de l’interleukine-8 par les ZOs : un mécanisme dépendant de NF-κB. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2015.02.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
30
|
Vuiblet V, Nguyen TT, Wynckel A, Fere M, Van-Gulick L, Untereiner V, Birembaut P, Rieu P, Piot O. Contribution of Raman spectroscopy in nephrology: a candidate technique to detect hydroxyethyl starch of third generation in osmotic renal lesions. Analyst 2015; 140:7382-90. [DOI: 10.1039/c5an00821b] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Raman spectroscopy, a candidate tool for detection of HES, a volume expander administrated after hemodynamic instability, in the kidney.
Collapse
Affiliation(s)
- V. Vuiblet
- UMR CNRS 7369 MEDyC
- Université de Reims Champagne-Ardenne
- Reims
- France
- Nephrology Division
| | - T. T. Nguyen
- UMR CNRS 7369 MEDyC
- Université de Reims Champagne-Ardenne
- Reims
- France
| | - A. Wynckel
- Nephrology Division
- Maison Blanche University Hospital
- Reims
- France
| | - M. Fere
- UMR CNRS 7369 MEDyC
- Université de Reims Champagne-Ardenne
- Reims
- France
| | - L. Van-Gulick
- UMR CNRS 7369 MEDyC
- Université de Reims Champagne-Ardenne
- Reims
- France
| | - V. Untereiner
- UMR CNRS 7369 MEDyC
- Université de Reims Champagne-Ardenne
- Reims
- France
| | - P. Birembaut
- Histology Laboratory Pol Bouin
- Maison Blanche University Hospital
- Reims
- France
| | - P. Rieu
- UMR CNRS 7369 MEDyC
- Université de Reims Champagne-Ardenne
- Reims
- France
- Nephrology Division
| | - O. Piot
- UMR CNRS 7369 MEDyC
- Université de Reims Champagne-Ardenne
- Reims
- France
- PICT (Cellular and Tissular Imaging Platform)
| |
Collapse
|
31
|
Perotin JM, Adam D, Vella-Boucaud J, Delepine G, Sandu S, Jonvel AC, Prevost A, Berthiot G, Pison C, Lebargy F, Birembaut P, Coraux C, Deslee G. Delay of airway epithelial wound repair in COPD is associated with airflow obstruction severity. Respir Res 2014; 15:151. [PMID: 25427655 PMCID: PMC4251925 DOI: 10.1186/s12931-014-0151-9] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2014] [Accepted: 11/11/2014] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Airway epithelium integrity is essential to maintain its role of mechanical and functional barrier. Recurrent epithelial injuries require a complex mechanism of repair to restore its integrity. In chronic obstructive pulmonary disease (COPD), an abnormal airway epithelial repair may participate in airway remodeling. The objective was to determine if airway epithelial wound repair of airway epithelium is abnormal in COPD. METHODS Patients scheduled for lung resection were prospectively recruited. Demographic, clinical data and pulmonary function tests results were recorded. Emphysema was visually scored and histological remodeling features were noted. Primary bronchial epithelial cells (BEC) were extracted and cultured for wound closure assay. We determined the mean speed of wound closure (MSWC) and cell proliferation index, matrix metalloprotease (MMP)-2, MMP-9 and cytokines levels in supernatants of BEC 18 hours after cell wounding. In a subset of patients, bronchiolar epithelial cells were also cultured for wound closure assay for MSWC analyze. RESULTS 13 COPD and 7 non COPD patients were included. The severity of airflow obstruction and the severity of emphysema were associated with a lower MSWC in BEC (p = 0.01, 95% CI [0.15-0.80]; p = 0.04, 95% CI [-0.77;-0.03] respectively). Cell proliferation index was decreased in COPD patients (19 ± 6% in COPD vs 27 ± 3% in non COPD, p = 0.04). The severity of COPD was associated with a lower level of MMP-2 (7.8 ± 2 10(5) AU in COPD GOLD D vs 12.8 ± 0.13 10(5) AU in COPD GOLD A, p = 0.04) and a lower level of IL-4 (p = 0.03, 95% CI [0.09;0.87]). Moreover, higher levels of IL-4 and IL-2 were associated with a higher MSWC (p = 0.01, 95% CI [0.17;0.89] and p = 0.02, 95% CI [0.09;0.87] respectively). Clinical characteristics and smoking history were not associated with MSWC, cell proliferation index or MMP and cytokines levels. Finally, we showed an association of the MSWC of bronchial and corresponding bronchiolar epithelial cells obtained from the same patients (p = 0.02, 95% CI [0.12;0.89]). CONCLUSION Our results showed an abnormal bronchial epithelial wound closure process in severe COPD. Further studies are needed to elucidate the contribution and the regulation of this mechanism in the complex pathophysiology of COPD.
Collapse
Affiliation(s)
- Jeanne-Marie Perotin
- Department of Respiratory Diseases, University Hospital, 45 rue Cognacq Jay, 51100, Reims, France.
- INSERM UMRS 903, University Hospital, Reims, France.
| | - Damien Adam
- INSERM UMRS 903, University Hospital, Reims, France.
| | - Juliette Vella-Boucaud
- Department of Respiratory Diseases, University Hospital, 45 rue Cognacq Jay, 51100, Reims, France.
| | - Gonzague Delepine
- Department of Cardio-Thoracic Surgery, University Hospital, Reims, France.
| | - Sebastian Sandu
- Department of Cardio-Thoracic Surgery, University Hospital, Reims, France.
| | - Anne-Carole Jonvel
- Department of Respiratory Medicine, Hospital, Charlevilles-Mezières, France.
| | | | - Gérard Berthiot
- Department of Respiratory Medicine, Hospital, Chalons en Champagne, France.
| | - Christophe Pison
- Clinique Universitaire de Pneumologie, Pôle Thorax et Vaisseaux, CHU Grenoble; Inserm1055; Université Joseph Fourier, Grenoble, France.
| | - François Lebargy
- Department of Respiratory Diseases, University Hospital, 45 rue Cognacq Jay, 51100, Reims, France.
| | - Philippe Birembaut
- INSERM UMRS 903, University Hospital, Reims, France.
- Department of anatomopathology, Pol Bouin Laboratory, University Hospital, Reims, France.
| | | | - Gaëtan Deslee
- Department of Respiratory Diseases, University Hospital, 45 rue Cognacq Jay, 51100, Reims, France.
- INSERM UMRS 903, University Hospital, Reims, France.
| |
Collapse
|
32
|
Joannes A, Grelet S, Duca L, Gilles C, Kileztky C, Dalstein V, Birembaut P, Polette M, Nawrocki-Raby B. Fhit Regulates EMT Targets through an EGFR/Src/ERK/Slug Signaling Axis in Human Bronchial Cells. Mol Cancer Res 2014; 12:775-83. [DOI: 10.1158/1541-7786.mcr-13-0386-t] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
33
|
Adam D, Perotin JM, Lebargy F, Birembaut P, Deslée G, Coraux C. [Regeneration of airway epithelium]. Rev Mal Respir 2013; 31:300-11. [PMID: 24750950 DOI: 10.1016/j.rmr.2013.11.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2013] [Accepted: 10/04/2013] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Epithelial regeneration is a complex process. It can lead to the remodeling of the airway epithelium as in asthma, COPD or cystic fibrosis. BACKGROUND The development of in vivo and in vitro models has allowed the analysis of remodeling mechanisms and showed the role of components of extracellular matrix, proteases, cytokines and growth factors. Airway epithelial progenitors and stems cells have been studied in these models. However, their identification remains difficult. CONCLUSION Identification and characterization of airway epithelial progenitor/stem-cells, and a better knowledge of the regeneration process may allow the development of new therapeutic strategies for airway epithelial reconstitution.
Collapse
Affiliation(s)
- D Adam
- Inserm UMRS 903, CHU de Reims, 45, rue Cognacq-Jay, 51092 Reims, France
| | - J-M Perotin
- Inserm UMRS 903, CHU de Reims, 45, rue Cognacq-Jay, 51092 Reims, France; Service des maladies respiratoires, CHU de Reims, 45, rue Cognacq-Jay, 51100 Reims, France
| | - F Lebargy
- Service des maladies respiratoires, CHU de Reims, 45, rue Cognacq-Jay, 51100 Reims, France
| | - P Birembaut
- Inserm UMRS 903, CHU de Reims, 45, rue Cognacq-Jay, 51092 Reims, France; Laboratoire d'histologie Pol Bouin, CHU de Reims, 45, rue Cognacq-Jay, 51092 Reims, France
| | - G Deslée
- Inserm UMRS 903, CHU de Reims, 45, rue Cognacq-Jay, 51092 Reims, France; Service des maladies respiratoires, CHU de Reims, 45, rue Cognacq-Jay, 51100 Reims, France.
| | - C Coraux
- Inserm UMRS 903, CHU de Reims, 45, rue Cognacq-Jay, 51092 Reims, France
| |
Collapse
|
34
|
Guyot-Colosio C, Vuiblet V, Barbe C, Toupance O, Lavaud S, Touré F, Birembaut P, Rieu P. Influence de l’expression du VEGF glomérulaire en transplantation rénale. Nephrol Ther 2013. [DOI: 10.1016/j.nephro.2013.07.159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
35
|
Vuiblet V, Feré M, Wynckel A, Bankole E, Birembaut P, Piot O, Rieu P. Accumulation et persistance d’hydroxyéthyl amidon 130/0,4 dans les greffons rénaux détectées par microspectroscopie Raman. Nephrol Ther 2013. [DOI: 10.1016/j.nephro.2013.07.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
Bessaci-Kabouya K, Gaultier B, Zahm JM, Coraux C, Mauran P, Weiss L, Dalphin ML, Derelle J, Tatopoulos A, Huet F, Perez-Martin S, Birembaut P, Abely M. 116 Effect of Staphylococcus aureus supernatant on airway epithelium functionality in infants with cystic fibrosis. J Cyst Fibros 2013. [DOI: 10.1016/s1569-1993(13)60258-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
37
|
Luczka E, Syne L, Nawrocki-Raby B, Kileztky C, Hunziker W, Birembaut P, Gilles C, Polette M. Regulation of membrane-type 1 matrix metalloproteinase expression by zonula occludens-2 in human lung cancer cells. Clin Exp Metastasis 2013; 30:833-43. [PMID: 23605953 DOI: 10.1007/s10585-013-9583-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2013] [Accepted: 04/08/2013] [Indexed: 01/11/2023]
Abstract
During tumor invasion, tumor epithelial cells acquire migratory and invasive properties involving important phenotypic alterations. Among these changes, one can observe reorganization or a loss of cell-cell adhesion complexes such as tight junctions (TJs). TJs are composed of transmembrane proteins (occludin, claudins) linked to the actin cytoskeleton through cytoplasmic adaptor molecules including those of the zonula occludens family (ZO-1, -2, -3). We here evaluated the potential role of ZO-2 in the acquisition of invasive properties by tumor cells. In vivo, we showed a decrease of ZO-2 expression in bronchopulmonary cancers, with a preferential localization in the cytoplasm. In addition, in vitro, the localization of ZO-2 varied according to invasive properties of tumor cells, with a cytoplasmic localization correlating with invasion. In addition, we demonstrated that ZO-2 inhibition increases invasive and migrative capacities of invasive tumor cells. This was associated with an increase of MT1-MMP. These results suggest that ZO-2, besides its structural role in tight junction assembly, can act also as a repressor of tumor progression through its ability to reduce the expression of tumor-promoting genes in invasive tumor cells.
Collapse
Affiliation(s)
- E Luczka
- INSERM UMR-S 903, SFR CAP-SANTE FED 4231, University of Reims-Champagne-Ardenne, 45, rue Cognacq-Jay, 51100, Reims, France
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Dauphin M, Barbe C, Lemaire S, Nawrocki-Raby B, Lagonotte E, Delepine G, Birembaut P, Gilles C, Polette M. Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas. Lung Cancer 2013; 81:117-22. [PMID: 23562674 DOI: 10.1016/j.lungcan.2013.03.011] [Citation(s) in RCA: 104] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2012] [Revised: 03/04/2013] [Accepted: 03/09/2013] [Indexed: 10/27/2022]
Abstract
Epithelial-to-mesenchymal transition (EMT) is believed to contribute to tumour invasion. Vimentin expression by carcinoma cells is a largely recognized marker of EMT. This study aimed at examining vimentin expression in non small cell lung carcinomas (NSCLC) by immunohistochemistry to evaluate potential correlations between vimentin expression and the differentiation status, the TNM stage and the outcome of the patients. 295 NSCLC including 164 squamous cell carcinomas (SCC), 108 adenocarcinomas (AC) and 23 other NSCLC carcinomas have been examined by immunohistochemistry. Vimentin was indeed detected in 145 cases (49.2%). It was principally present in isolated tumour cells and invasive clusters, particularly in cells at the tumour/stroma interface. Vimentin expression was significantly more expressed in large cell neuroendocrine, adeno-squamous and sarcomatoid carcinomas than in SCC and AC and was significantly associated with the differentiation status of carcinomas. The follow-up of 193 patients further demonstrated that an extensive expression of vimentin (>50% of tumour cells) was associated with the occurrence of metastases. In conclusion, our data demonstrate that vimentin expression is a frequent event in NSCLC and that its expression can be associated with a lack of differentiation and the occurrence of metastases.
Collapse
Affiliation(s)
- Maryline Dauphin
- INSERM UMR-S 903, SFR CAP-Santé, University of Reims-Champagne-Ardenne, 51100 Reims, France
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Dauphin M, Barbe C, Lemaire S, Lagonotte E, Delepine G, Birembaut P, Gilles C, Polette M. Rôle pronostique de la vimentine comme marqueur de transition épithélio-mésenchymateuse dans les carcinomes non à petites cellules du poumon. Ann Pathol 2012. [DOI: 10.1016/j.annpat.2012.09.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
40
|
Adam D, Roux J, Lingée S, Nawrocki-Raby B, Birembaut P, Coraux C. WS2.5 Airway epithelial regeneration is abnormal in CF in absence of endogenous infection and inflammation. J Cyst Fibros 2012. [DOI: 10.1016/s1569-1993(12)60014-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
41
|
Joannes A, Birembaut P, Nawrocki-Raby B. Implication du gène Fhit dans la régulation de l’invasion tumorale. Rev Mal Respir 2012. [DOI: 10.1016/j.rmr.2011.10.966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
42
|
Rotondo S, Menard J, Durlach A, Birembaut P, Staerman F. Endothéline-1 et récepteur A : valeur pronostique pour la reprise évolutive biologique dans l’adénocarcinome de prostate localement avancé et métastatique ganglionnaire. Prog Urol 2012; 22:38-44. [DOI: 10.1016/j.purol.2011.08.038] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2011] [Revised: 08/21/2011] [Accepted: 08/23/2011] [Indexed: 10/17/2022]
|
43
|
Bonnomet A, Syne L, Brysse A, Feyereisen E, Thompson EW, Noël A, Foidart JM, Birembaut P, Polette M, Gilles C. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene 2011; 31:3741-53. [PMID: 22120722 DOI: 10.1038/onc.2011.540] [Citation(s) in RCA: 145] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Epithelial-to-mesenchymal transition (EMT) processes endow epithelial cells with enhanced migratory/invasive properties and are therefore likely to contribute to tumor invasion and metastatic spread. Because of the difficulty in following EMT processes in human tumors, we have developed and characterized an animal model with transplantable human breast tumor cells (MDA-MB-468) uniquely showing spontaneous EMT events to occur. Using vimentin as a marker of EMT, heterogeneity was revealed in the primary MDA-MB-468 xenografts with vimentin-negative and vimentin-positive areas, as also observed on clinical human invasive breast tumor specimens. Reverse transcriptase-PCR after microdissection of these populations from the xenografts revealed EMT traits in the vimentin-positive zones characterized by enhanced 'mesenchymal gene' expression (Snail, Slug and fibroblast-specific protein-1) and diminished expression of epithelial molecules (E-cadherin, ZO-3 and JAM-A). Circulating tumor cells (CTCs) were detected in the blood as soon as 8 days after s.c. injection, and lung metastases developed in all animals injected as examined by in vivo imaging analyses and histology. High levels of vimentin RNA were detected in CTCs by reverse transcriptase-quantitative PCR as well as, to a lesser extent, Snail and Slug RNA. Von Willebrand Factor/vimentin double immunostainings further showed that tumor cells in vascular tumoral emboli all expressed vimentin. Tumoral emboli in the lungs also expressed vimentin whereas macrometastases displayed heterogenous vimentin expression, as seen in the primary xenografts. In conclusion, our data uniquely demonstrate in an in vivo context that EMT occurs in the primary tumors, and associates with an enhanced ability to intravasate and generate CTCs. They further suggest that mesenchymal-to-epithelial phenomena occur in secondary organs, facilitating the metastatic growth.
Collapse
Affiliation(s)
- A Bonnomet
- Laboratory of Tumor and Developmental Biology, GIGA-Cancer, University of Liège, Liège, Belgium
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Brysse A, Mestdagt M, Polette M, Luczka E, Hunziker W, Noël A, Birembaut P, Foidart JM, Gilles C. Regulation of CXCL8/IL-8 Expression by Zonula Occludens-1 in Human Breast Cancer Cells. Mol Cancer Res 2011; 10:121-32. [DOI: 10.1158/1541-7786.mcr-11-0180] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Marcet B, Chevalier B, Luxardi G, Coraux C, Zaragosi LE, Cibois M, Robbe-Sermesant K, Jolly T, Cardinaud B, Moreilhon C, Giovannini-Chami L, Nawrocki-Raby B, Birembaut P, Waldmann R, Kodjabachian L, Barbry P. Erratum: Control of vertebrate multiciliogenesis by miR-449 through direct repression of the Delta/Notch pathway. Nat Cell Biol 2011. [DOI: 10.1038/ncb2358] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
46
|
Zahm JM, Milliot M, Bresin A, Coraux C, Birembaut P. The effect of hyaluronan on airway mucus transport and airway epithelial barrier integrity: potential application to the cytoprotection of airway tissue. Matrix Biol 2011; 30:389-95. [PMID: 21839834 DOI: 10.1016/j.matbio.2011.07.003] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2011] [Revised: 07/27/2011] [Accepted: 07/27/2011] [Indexed: 10/17/2022]
Abstract
The lubricating abilities and the protective functions of hyaluronan, a structural component of interstitial and connective tissues, were assessed in in vitro models of airway mucus transport and epithelial barrier. We found that hyaluronan enhanced the transport of airway mucus by cilia and by cough: the lower the hyaluronan molecular weight, the higher the increase. By immunofluorescence and western blot, we observed a significant dose-dependent (0.1, 1, 5 and 10 mg/ml) increase by low molecular weight hyaluronan (40 kDa) in the expression of tight junction proteins such as ZO-1, as well as an increase in the trans-epithelial resistance. Incubation of airway epithelial cells with hyaluronan 40 kDa also significantly increased the gap junction functionality. Finally, we demonstrated that hyaluronan 40 kDa protects the airway epithelium against injury induced by bacterial products during infection. These results demonstrate that the expression and functionality of intercellular adhesion molecules are increased by hyaluronan which can also act as a lubricant at the airway epithelium surface and suggest that hyaluronan may play a therapeutic role in a variety of respiratory diseases.
Collapse
|
47
|
Vuiblet V, Birembaut P, François A, Cordonnier C, Noel LH, Goujon JM, Paraf F, Machet MC, Girardot-Seguin S, Lebranchu Y, Rieu P. Sirolimus-based regimen is associated with decreased expression of glomerular vascular endothelial growth factor. Nephrol Dial Transplant 2011; 27:411-6. [PMID: 21617191 DOI: 10.1093/ndt/gfr261] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
BACKGROUND Sirolimus (SRL) is a potent immunosuppressant used in organ transplantation. It is known to decrease vascular endothelial growth factor (VEGF) synthesis, making it an interesting treatment option for transplant patients who develop Kaposi sarcoma or other malignant diseases. Because VEGF plays a key role in glomerular function and vascular remodelling, we determined the effect of SRL on renal VEGF expression. METHODS Using immunohistochemistry and quantitative image analysis, we examined renal VEGF expression in routine kidney biopsies performed at 1 year post-transplant in the CONCEPT study, a prospective randomized study comparing a cyclosporine (CsA)-based regimen to a SRL-based regimen in association with mycophenolate mofetil (MMF). RESULTS A total of 74 patients were included in this substudy; 35 were randomized to the CsA group and 39 to the SRL group. Using continuous variables, the mean percentage of glomerular VEGF expression at Week 52 was significantly lower in the SRL group (14.7 ± 13%) compared to CsA group (21.2 ± 14%: P = 0.02). The percentage of glomerular VEGF expression at Week 52 was not influenced by recipient or donor age, gender, renal function, CsA dose, CsA blood level, SRL dose or SRL blood level. It was significantly lower in patients with a proteinuria over versus below 0.5 g/day (11.58 ± 7.9 versus 19.45 ± 15.53; P = 0.036). CONCLUSIONS There is emerging evidence that the VEGF system can play either a beneficial or a detrimental role depending on the specific pathologic situations. Therefore, modulating the renal VEGF axis by using an SRL-based regimen may influence the evolution of kidney injury associated with renal transplantation.
Collapse
Affiliation(s)
- Vincent Vuiblet
- Department of Nephrology and Transplantation, University Hospital, Reims, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Lacau Saint Guily J, Pretet J, Agius G, Rousseau A, Barry B, Dufour X, Perie S, Lefevre M, Birembaut P, Mougin C, Simon T, Clavel C. PAPILLOPHAR: Impact of the human papillomavirus (HPV) status in the prognosis of oropharynx squamous cell carcinoma (OSCC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps198] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
49
|
Krais AM, Hautefeuille AH, Cros MP, Krutovskikh V, Tournier JM, Birembaut P, Thépot A, Paliwal A, Herceg Z, Boffetta P, Brennan P, Hainaut PL. CHRNA5 as negative regulator of nicotine signaling in normal and cancer bronchial cells: effects on motility, migration and p63 expression. Carcinogenesis 2011; 32:1388-95. [PMID: 21586512 DOI: 10.1093/carcin/bgr090] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Genome-wide association studies have linked lung cancer risk with a region of chromosome 15q25.1 containing CHRNA3, CHRNA5 and CHRNB4 encoding α3, α5 and β4 subunits of nicotinic acetylcholine receptors (nAChR), respectively. One of the strongest associations was observed for a non-silent single-nucleotide polymorphism at codon 398 in CHRNA5. Here, we have used pharmacological (antagonists) or genetic (RNA interference) interventions to modulate the activity of CHRNA5 in non-transformed bronchial cells and in lung cancer cell lines. In both cell types, silencing CHRNA5 or inhibiting receptors containing nAChR α5 with α-conotoxin MII exerted a nicotine-like effect, with increased motility and invasiveness in vitro and increasing calcium influx. The effects on motility were enhanced by addition of nicotine but blocked by inhibiting CHRNA7, which encodes the homopentameric receptor α7 subunit. Silencing CHRNA5 also decreased the expression of cell adhesion molecules P120 and ZO-1 in lung cancer cells as well as the expression of DeltaNp63α in squamous cell carcinoma cell lines. These results demonstrate a role for CHRNA5 in modulating adhesion and motility in bronchial cells, as well as in regulating p63, a potential oncogene in squamous cell carcinoma.
Collapse
Affiliation(s)
- Annette M Krais
- Group of Molecular Carcinogenesis, 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Ghoneim C, Kaoma T, Nicot N, François B, Nazarov P, Muller A, Birembaut P, Vallar L. Abstract 3905: Identification of new tumor-specific splice variants in NSCL cancers by whole genome exon arrays. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-3905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Although lung cancer is one of the major causes of cancer death in men and women worldwide, the molecular pathogenesis of this disease remains elusive. The contribution of alternative splicing (AS) to cancer pathogenesis and progression is emerging as an area of considerable interest. Cancer-specific splice variants seem to play a key role in disease mechanism and etiology.
In this study, we analyzed 20 matched pairs of tumor specimens of Adenocarcinomas (AC), Squamous Cell Carcinomas (SCC) and adjacent normal tissue using Affymetrix GeneChip Exon microarrays. With this technology, it is possible to profile simultaneously gene expression and alternative splicing patterns for the entire genome using a single array. At the exon level, multiple probes for each exon enable the discrimination among different isoforms of a gene. Total RNA from tumors or normal tissue samples were amplified using the Ambion whole transcript expression kit and were hybridized onto GeneChip Human Exon 1.0 ST Array®. Data generated were normalized using RMA and were subjected to several layers of filtering (DABG filter, Multiple mRNAs filter). The delta splice index (ΔSI) was calculated, and alternative splicing events were detected using MIDAS and Rank Product method. Probesets were ranked based on their SI p-values.
By comparing tumor samples to the corresponding normal subgroups, we generated a list of 1689 splice variant candidates for SCC and 1010 for AC showing significant differential expression between normal and tumor tissues. Top candidates in each tumor subtype were selected based on their ΔSI for manual inspection and further bioinformatics analysis. Study of alternatively spliced candidates revealed that approximately 30 % of the genes were detected in both types of cancer. Gene function analysis combining text mining and knowledge-based approaches indicated that the largest subset (70 %) of these genes was related to cancer. Within this group, 30% of genes were related to lung cancers. Interestingly the major part (85%) of variant candidates was not previously associated with AS events in cancer. We focused our attention on this latter group and, through validation by RT/PCR, confirmed the existence of new specific alternative splicing events occurring in each cancer type. In addition, we identified biological pathways and gene networks that are specifically altered in AC or SCC. The cancer-specific AS variants and pathways identified in our study are promising biomarkers and targets for diagnostic or therapeutic purposes.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3905. doi:10.1158/1538-7445.AM2011-3905
Collapse
Affiliation(s)
| | - Tony Kaoma
- 1Microarray center CRP-SANTE, Luxembourg, Luxembourg
| | | | | | - Petr Nazarov
- 1Microarray center CRP-SANTE, Luxembourg, Luxembourg
| | - Arnaud Muller
- 1Microarray center CRP-SANTE, Luxembourg, Luxembourg
| | | | | |
Collapse
|